Checked on CIViC,PMID,cDNA_Position,Multiple Mutants in Case,Mutation Event c.DNA.,Transcript Reference,Predicted Consequence Protein Change,variant_name,Mutation Type,Kindred Case,Confirmed De Novo,Phenotype (for reference),Phenotype,Reference,Age,Sex,Notes,Evidence Statements,Resolution,Input,Warnings,HGVS_transcript,HGVS_intronic_chr_context,HGVS_intronic_rsg_context,HGVS_RefSeqGene,HGVS_LRG,HGVS_LRG_transcript,HGVS_Predicted_Protein,HGVS_Genomic_GRCh37,GRCh37_CHR,GRCh37_POS,GRCh37_ID,GRCh37_REF,GRCh37_ALT,HGVS_Genomic_GRCh38,GRCh38_CHR,GRCh38_POS,GRCh38_ID,GRCh38_REF,GRCh38_ALT,Gene_Symbol,HGNC_Gene_ID,Transcript_description,Alt_genomic_loci
Yes,24986515,280,No,c.280G>T,NM_000551.3,p.Glu94*,E94* (c.280G>T),stop_gained,3,No,,HP:0010797; HP:0005584; HP:0002666,"(Ning et al., 2014)",E53Y0M; LK54Y0M,M,Chinese,"23 patients from 12 families diagnosed with hereditary VHL disease at the Peking University First Hospital Department of Urology were described as part of a broader study examining telomere length and anticipation. Family 3 involved two members with a c.280G>T change leading to a p.Glu94Stop protein change. The first member, a male, presented with hemangioblastoma at age 54 and renal cell carcinoma and pheochromocytoma at age 53. The second member, also male, presented with papillary cystadenoma of the epididymis at 23, renal cell carcinoma at 29, and pancreatic cysts at 29. No other family members were described. ACMG Evidence Code: 'PP4' because the patients' phenotypes and family histories are highly specific for VHL disease.",Patient,NM_000551.3:c.280G>T,,NM_000551.3:c.280G>T,,,NG_008212.3:g.5493G>T,LRG_322:g.5493G>T,LRG_322t1:c.280G>T,NP_000542.1(LRG_322p1):p.(Glu94Ter),NC_000003.11:g.10183811G>T,3,10183811,.,G,T,NC_000003.12:g.10142127G>T,3,10142127,.,G,T,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,24986515,280,No,c.280G>T,NM_000551.3,p.Glu94*,E94* (c.280G>T),stop_gained,3,No,,HP:0005584; HP:0001737; HP:0009715,"(Ning et al., 2014)",E23Y0M; LK29Y0M,M,Chinese,"23 patients from 12 families diagnosed with hereditary VHL disease at the Peking University First Hospital Department of Urology were described as part of a broader study examining telomere length and anticipation. Family 3 involved two members with a c.280G>T change leading to a p.Glu94Stop protein change. The first member, a male, presented with hemangioblastoma at age 54 and renal cell carcinoma and pheochromocytoma at age 53. The second member, also male, presented with papillary cystadenoma of the epididymis at 23, renal cell carcinoma at 29, and pancreatic cysts at 29. No other family members were described. ACMG Evidence Code: 'PP4' because the patients' phenotypes and family histories are highly specific for VHL disease.",Patient,NM_000551.3:c.280G>T,,NM_000551.3:c.280G>T,,,NG_008212.3:g.5493G>T,LRG_322:g.5493G>T,LRG_322t1:c.280G>T,NP_000542.1(LRG_322p1):p.(Glu94Ter),NC_000003.11:g.10183811G>T,3,10183811,.,G,T,NC_000003.12:g.10142127G>T,3,10142127,.,G,T,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,24986515,280,No,c.280G>T,NM_000551.3,p.Glu94*,E94* (c.280G>T),stop_gained,12,No,,HP:0010797,"(Ning et al., 2014)",E31Y0M; LK31Y0M,M,Chinese,"23 patients from 12 families diagnosed with hereditary VHL disease at the Peking University First Hospital Department of Urology were described as part of a broader study examining telomere length and anticipation. Family 12 involved one individual with a c.280T>G mutation leading to a p.Glu94Stop change, presenting with hemangioblastoma at 31. ACMG Evidence Code: 'PP4' because the patients' phenotypes and family histories are highly specific for VHL disease. 'PM4' because of the protein length change caused by the heavily premature stop codon.",Patient,NM_000551.3:c.280G>T,,NM_000551.3:c.280G>T,,,NG_008212.3:g.5493G>T,LRG_322:g.5493G>T,LRG_322t1:c.280G>T,NP_000542.1(LRG_322p1):p.(Glu94Ter),NC_000003.11:g.10183811G>T,3,10183811,.,G,T,NC_000003.12:g.10142127G>T,3,10142127,.,G,T,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,24986515,269,No,c.269A>T,NM_000551.3,p.Asn90Ile,N90I (c.269A>T),missense_variant,4,No,,HP:0005584,"(Ning et al., 2014)",E63Y0M; LK60Y0M,F,Chinese,"23 patients from 12 families diagnosed with hereditary VHL disease at the Peking University First Hospital Department of Urology were described as part of a broader study examining telomere length and anticipation. Family 4 involved two members with a c.269A>T change leading to a p.Asn90Ile protein change. The first member, a female, presented with renal cell carcinoma at 63. The second member, also male, presented with hemangioblastoma at 22 and retinal capillary hemangioma at 32. The third individual a male, presented with hemangioblastoma at 28, renal cell carcinoma at 38, and pancreatic cysts at 38. ACMG Evidence Code: 'PP4' because the patients' phenotypes and family histories are highly specific for VHL disease. ",Patient,NM_000551.3:c.269A>T,,NM_000551.3:c.269A>T,,,NG_008212.3:g.5482A>T,LRG_322:g.5482A>T,LRG_322t1:c.269A>T,NP_000542.1(LRG_322p1):p.(Asn90Ile),NC_000003.11:g.10183800A>T,3,10183800,.,A,T,NC_000003.12:g.10142116A>T,3,10142116,.,A,T,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,24986515,269,No,c.269A>T,NM_000551.3,p.Asn90Ile,N90I (c.269A>T),missense_variant,4,No,,HP:0010797; HP:0009711,"(Ning et al., 2014)",E22Y0M; LK32Y0M,F,Chinese,"23 patients from 12 families diagnosed with hereditary VHL disease at the Peking University First Hospital Department of Urology were described as part of a broader study examining telomere length and anticipation. Family 4 involved two members with a c.269A>T change leading to a p.Asn90Ile protein change. The first member, a female, presented with renal cell carcinoma at 63. The second member, also male, presented with hemangioblastoma at 22 and retinal capillary hemangioma at 32. The third individual a male, presented with hemangioblastoma at 28, renal cell carcinoma at 38, and pancreatic cysts at 38. ACMG Evidence Code: 'PP4' because the patients' phenotypes and family histories are highly specific for VHL disease. ",Patient,NM_000551.3:c.269A>T,,NM_000551.3:c.269A>T,,,NG_008212.3:g.5482A>T,LRG_322:g.5482A>T,LRG_322t1:c.269A>T,NP_000542.1(LRG_322p1):p.(Asn90Ile),NC_000003.11:g.10183800A>T,3,10183800,.,A,T,NC_000003.12:g.10142116A>T,3,10142116,.,A,T,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,24986515,269,No,c.269A>T,NM_000551.3,p.Asn90Ile,N90I (c.269A>T),missense_variant,9,No,,HP:0010797; HP:0005584; HP:0001737,"(Ning et al., 2014)",E28Y0M; LK38Y0M,M,Chinese,"23 patients from 12 families diagnosed with hereditary VHL disease at the Peking University First Hospital Department of Urology were described as part of a broader study examining telomere length and anticipation. Family 4 involved two members with a c.269A>T change leading to a p.Asn90Ile protein change. The first member, a female, presented with renal cell carcinoma at 63. The second member, also male, presented with hemangioblastoma at 22 and retinal capillary hemangioma at 32. The third individual a male, presented with hemangioblastoma at 28, renal cell carcinoma at 38, and pancreatic cysts at 38. ACMG Evidence Code: 'PP4' because the patients' phenotypes and family histories are highly specific for VHL disease. ",Patient,NM_000551.3:c.269A>T,,NM_000551.3:c.269A>T,,,NG_008212.3:g.5482A>T,LRG_322:g.5482A>T,LRG_322t1:c.269A>T,NP_000542.1(LRG_322p1):p.(Asn90Ile),NC_000003.11:g.10183800A>T,3,10183800,.,A,T,NC_000003.12:g.10142116A>T,3,10142116,.,A,T,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,24986515,499,No,c.499C>T,NM_000551.3,p.Arg167Trp,R167W (c.499C>T),missense_variant,5,No,,HP:0005584,"(Ning et al., 2014)",E630M; LK63Y0M,M,Chinese,"23 patients from 12 families diagnosed with hereditary VHL disease at the Peking University First Hospital Department of Urology were described as part of a broader study examining telomere length and anticipation. Family 5 involved four members with a c.499C>T change leading to a p.Arg167Trp protein change. The first member, a male, presented with renal cell carcinoma at 63. The second member, a female presented with hemangioblastoma, renal cell carcinoma, ovarian cyst, and pancreatic cysts at 37, as well as pheochromocytoma at 39. The third member, a female, presented with pancreatic cysts at 36 and hemangioblastoma at 38. The fourth member, a female, presented with retinal capillary hemangioma at 34. ACMG Evidence Code: 'PP4' because the patients' phenotypes and family histories are highly specific for VHL disease.",Patient,NM_000551.3:c.499C>T,,NM_000551.3:c.499C>T,,,NG_008212.3:g.13188C>T,LRG_322:g.13188C>T,LRG_322t1:c.499C>T,NP_000542.1(LRG_322p1):p.(Arg167Trp),NC_000003.11:g.10191506C>T,3,10191506,.,C,T,NC_000003.12:g.10149822C>T,3,10149822,.,C,T,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,24986515,499,No,c.499C>T,NM_000551.3,p.Arg167Trp,R167W (c.499C>T),missense_variant,5,No,,HP:0010797; HP:0005584; HP:0000138; HP:0001737; HP:0002666,"(Ning et al., 2014)",E37Y0M; LK29Y0M,F,Chinese,"23 patients from 12 families diagnosed with hereditary VHL disease at the Peking University First Hospital Department of Urology were described as part of a broader study examining telomere length and anticipation. Family 5 involved four members with a c.499C>T change leading to a p.Arg167Trp protein change. The first member, a male, presented with renal cell carcinoma at 63. The second member, a female presented with hemangioblastoma, renal cell carcinoma, ovarian cyst, and pancreatic cysts at 37, as well as pheochromocytoma at 39. The third member, a female, presented with pancreatic cysts at 36 and hemangioblastoma at 38. The fourth member, a female, presented with retinal capillary hemangioma at 34. ACMG Evidence Code: 'PP4' because the patients' phenotypes and family histories are highly specific for VHL disease.",Patient,NM_000551.3:c.499C>T,,NM_000551.3:c.499C>T,,,NG_008212.3:g.13188C>T,LRG_322:g.13188C>T,LRG_322t1:c.499C>T,NP_000542.1(LRG_322p1):p.(Arg167Trp),NC_000003.11:g.10191506C>T,3,10191506,.,C,T,NC_000003.12:g.10149822C>T,3,10149822,.,C,T,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,24986515,499,No,c.499C>T,NM_000551.3,p.Arg167Trp,R167W (c.499C>T),missense_variant,5,No,,HP:0010797; HP:0001737,"(Ning et al., 2014)",E36Y0M; LK38Y0M,F,Chinese,"23 patients from 12 families diagnosed with hereditary VHL disease at the Peking University First Hospital Department of Urology were described as part of a broader study examining telomere length and anticipation. Family 5 involved four members with a c.499C>T change leading to a p.Arg167Trp protein change. The first member, a male, presented with renal cell carcinoma at 63. The second member, a female presented with hemangioblastoma, renal cell carcinoma, ovarian cyst, and pancreatic cysts at 37, as well as pheochromocytoma at 39. The third member, a female, presented with pancreatic cysts at 36 and hemangioblastoma at 38. The fourth member, a female, presented with retinal capillary hemangioma at 34. ACMG Evidence Code: 'PP4' because the patients' phenotypes and family histories are highly specific for VHL disease.",Patient,NM_000551.3:c.499C>T,,NM_000551.3:c.499C>T,,,NG_008212.3:g.13188C>T,LRG_322:g.13188C>T,LRG_322t1:c.499C>T,NP_000542.1(LRG_322p1):p.(Arg167Trp),NC_000003.11:g.10191506C>T,3,10191506,.,C,T,NC_000003.12:g.10149822C>T,3,10149822,.,C,T,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,24986515,499,No,c.499C>T,NM_000551.3,p.Arg167Trp,R167W (c.499C>T),missense_variant,5,No,,HP:0009711,"(Ning et al., 2014)",E34Y0M; LK34Y0M,F,Chinese,"23 patients from 12 families diagnosed with hereditary VHL disease at the Peking University First Hospital Department of Urology were described as part of a broader study examining telomere length and anticipation. Family 5 involved four members with a c.499C>T change leading to a p.Arg167Trp protein change. The first member, a male, presented with renal cell carcinoma at 63. The second member, a female presented with hemangioblastoma, renal cell carcinoma, ovarian cyst, and pancreatic cysts at 37, as well as pheochromocytoma at 39. The third member, a female, presented with pancreatic cysts at 36 and hemangioblastoma at 38. The fourth member, a female, presented with retinal capillary hemangioma at 34. ACMG Evidence Code: 'PP4' because the patients' phenotypes and family histories are highly specific for VHL disease.",Patient,NM_000551.3:c.499C>T,,NM_000551.3:c.499C>T,,,NG_008212.3:g.13188C>T,LRG_322:g.13188C>T,LRG_322t1:c.499C>T,NP_000542.1(LRG_322p1):p.(Arg167Trp),NC_000003.11:g.10191506C>T,3,10191506,.,C,T,NC_000003.12:g.10149822C>T,3,10149822,.,C,T,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,24986515,349,No,c.349T>G,NM_000551.3,p.Trp117Gly,W117G (c.349T>G),missense_variant,7,No,,HP:0010797; HP:0001737; HP:0005584; HP:0009711,"(Ning et al., 2014)",E36Y0M; LK44Y0M,M,Chinese,"23 patients from 12 families diagnosed with hereditary VHL disease at the Peking University First Hospital Department of Urology were described as part of a broader study examining telomere length and anticipation. Family 7 involved five members with a c.349T>G change leading to a p.Trp117Gly protein change. The first member, a male, presented with hemangioblastoma at 36, pancreatic cysts at 40, renal cell carcinoma at 44, and retinal capillary hemangioma at 44. The second member, a male, presented with hemangioblastoma at 13. The third member, a male, presented with papillary cystadenoma of the epididymis at 37. The fourth member, a female, presented with retinal capillary hemangiomas at 13. The fifth member, a male, presented with retinal capillary hemangiomas at 11, and hemangioblastoma at 12. ACMG Evidence Code: 'PP4' because the patients' phenotypes and family histories are highly specific for VHL disease.",Patient,NM_000551.3:c.349T>G,,NM_000551.3:c.349T>G,,,NG_008212.3:g.9888T>G,LRG_322:g.9888T>G,LRG_322t1:c.349T>G,NP_000542.1(LRG_322p1):p.(Trp117Gly),NC_000003.11:g.10188206T>G,3,10188206,.,T,G,NC_000003.12:g.10146522T>G,3,10146522,.,T,G,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,24986515,349,No,c.349T>G,NM_000551.3,p.Trp117Gly,W117G (c.349T>G),missense_variant,7,No,,HP:0010797,"(Ning et al., 2014)",E13Y0M; LK13Y0M,M,Chinese,"23 patients from 12 families diagnosed with hereditary VHL disease at the Peking University First Hospital Department of Urology were described as part of a broader study examining telomere length and anticipation. Family 7 involved five members with a c.349T>G change leading to a p.Trp117Gly protein change. The first member, a male, presented with hemangioblastoma at 36, pancreatic cysts at 40, renal cell carcinoma at 44, and retinal capillary hemangioma at 44. The second member, a male, presented with hemangioblastoma at 13. The third member, a male, presented with papillary cystadenoma of the epididymis at 37. The fourth member, a female, presented with retinal capillary hemangiomas at 13. The fifth member, a male, presented with retinal capillary hemangiomas at 11, and hemangioblastoma at 12. ACMG Evidence Code: 'PP4' because the patients' phenotypes and family histories are highly specific for VHL disease.",Patient,NM_000551.3:c.349T>G,,NM_000551.3:c.349T>G,,,NG_008212.3:g.9888T>G,LRG_322:g.9888T>G,LRG_322t1:c.349T>G,NP_000542.1(LRG_322p1):p.(Trp117Gly),NC_000003.11:g.10188206T>G,3,10188206,.,T,G,NC_000003.12:g.10146522T>G,3,10146522,.,T,G,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,24986515,349,No,c.349T>G,NM_000551.3,p.Trp117Gly,W117G (c.349T>G),missense_variant,7,No,,HP:0009715,"(Ning et al., 2014)",E37Y0M; LK37Y0M,M,Chinese,"23 patients from 12 families diagnosed with hereditary VHL disease at the Peking University First Hospital Department of Urology were described as part of a broader study examining telomere length and anticipation. Family 7 involved five members with a c.349T>G change leading to a p.Trp117Gly protein change. The first member, a male, presented with hemangioblastoma at 36, pancreatic cysts at 40, renal cell carcinoma at 44, and retinal capillary hemangioma at 44. The second member, a male, presented with hemangioblastoma at 13. The third member, a male, presented with papillary cystadenoma of the epididymis at 37. The fourth member, a female, presented with retinal capillary hemangiomas at 13. The fifth member, a male, presented with retinal capillary hemangiomas at 11, and hemangioblastoma at 12. ACMG Evidence Code: 'PP4' because the patients' phenotypes and family histories are highly specific for VHL disease.",Patient,NM_000551.3:c.349T>G,,NM_000551.3:c.349T>G,,,NG_008212.3:g.9888T>G,LRG_322:g.9888T>G,LRG_322t1:c.349T>G,NP_000542.1(LRG_322p1):p.(Trp117Gly),NC_000003.11:g.10188206T>G,3,10188206,.,T,G,NC_000003.12:g.10146522T>G,3,10146522,.,T,G,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,24986515,349,No,c.349T>G,NM_000551.3,p.Trp117Gly,W117G (c.349T>G),missense_variant,7,No,,HP:0009711,"(Ning et al., 2014)",E13Y0M; LK13Y0M,F,Chinese,"23 patients from 12 families diagnosed with hereditary VHL disease at the Peking University First Hospital Department of Urology were described as part of a broader study examining telomere length and anticipation. Family 7 involved five members with a c.349T>G change leading to a p.Trp117Gly protein change. The first member, a male, presented with hemangioblastoma at 36, pancreatic cysts at 40, renal cell carcinoma at 44, and retinal capillary hemangioma at 44. The second member, a male, presented with hemangioblastoma at 13. The third member, a male, presented with papillary cystadenoma of the epididymis at 37. The fourth member, a female, presented with retinal capillary hemangiomas at 13. The fifth member, a male, presented with retinal capillary hemangiomas at 11, and hemangioblastoma at 12. ACMG Evidence Code: 'PP4' because the patients' phenotypes and family histories are highly specific for VHL disease.",Patient,NM_000551.3:c.349T>G,,NM_000551.3:c.349T>G,,,NG_008212.3:g.9888T>G,LRG_322:g.9888T>G,LRG_322t1:c.349T>G,NP_000542.1(LRG_322p1):p.(Trp117Gly),NC_000003.11:g.10188206T>G,3,10188206,.,T,G,NC_000003.12:g.10146522T>G,3,10146522,.,T,G,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,24986515,349,No,c.349T>G,NM_000551.3,p.Trp117Gly,W117G (c.349T>G),missense_variant,7,No,,HP:0009711; HP:0010797,"(Ning et al., 2014)",E11Y0M; LK12Y0M,M,Chinese,"23 patients from 12 families diagnosed with hereditary VHL disease at the Peking University First Hospital Department of Urology were described as part of a broader study examining telomere length and anticipation. Family 7 involved five members with a c.349T>G change leading to a p.Trp117Gly protein change. The first member, a male, presented with hemangioblastoma at 36, pancreatic cysts at 40, renal cell carcinoma at 44, and retinal capillary hemangioma at 44. The second member, a male, presented with hemangioblastoma at 13. The third member, a male, presented with papillary cystadenoma of the epididymis at 37. The fourth member, a female, presented with retinal capillary hemangiomas at 13. The fifth member, a male, presented with retinal capillary hemangiomas at 11, and hemangioblastoma at 12. ACMG Evidence Code: 'PP4' because the patients' phenotypes and family histories are highly specific for VHL disease.",Patient,NM_000551.3:c.349T>G,,NM_000551.3:c.349T>G,,,NG_008212.3:g.9888T>G,LRG_322:g.9888T>G,LRG_322t1:c.349T>G,NP_000542.1(LRG_322p1):p.(Trp117Gly),NC_000003.11:g.10188206T>G,3,10188206,.,T,G,NC_000003.12:g.10146522T>G,3,10146522,.,T,G,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,24986515,533,No,c.533T>G,NM_000551.3,p.Leu178Arg,L178R (c.533T>G),missense_variant,10,No,,HP:0010797; HP:0009711; HP:0005584; HP:0001737,"(Ning et al., 2014)",E39Y0M; LK57Y0M,M,Chinese,"23 patients from 12 families diagnosed with hereditary VHL disease at the Peking University First Hospital Department of Urology were described as part of a broader study examining telomere length and anticipation. Family 10 involved two individuals with a c.533T>G mutation leading to a p.Leu178Arg change. The first individual, a male, presented with hemangioblastoma at 38, retinal capillary hemangioma at 57, renal cell carcinoma at 57, and pancreatic cysts at 57. The second individual, a male, presented with renal cell carcinoma at 30. ACMG Evidence Code: 'PP4' because the patients' phenotypes and family histories are highly specific for VHL disease.",Patient,NM_000551.3:c.533T>G,,NM_000551.3:c.533T>G,,,NG_008212.3:g.13222T>G,LRG_322:g.13222T>G,LRG_322t1:c.533T>G,NP_000542.1(LRG_322p1):p.(Leu178Arg),NC_000003.11:g.10191540T>G,3,10191540,.,T,G,NC_000003.12:g.10149856T>G,3,10149856,.,T,G,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,24986515,533,No,c.533T>G,NM_000551.3,p.Leu178Arg,L178R (c.533T>G),missense_variant,10,No,,HP:0005584,"(Ning et al., 2014)",E30Y0M; LK30Y0M,M,Chinese,"23 patients from 12 families diagnosed with hereditary VHL disease at the Peking University First Hospital Department of Urology were described as part of a broader study examining telomere length and anticipation. Family 10 involved two individuals with a c.533T>G mutation leading to a p.Leu178Arg change. The first individual, a male, presented with hemangioblastoma at 38, retinal capillary hemangioma at 57, renal cell carcinoma at 57, and pancreatic cysts at 57. The second individual, a male, presented with renal cell carcinoma at 30. ACMG Evidence Code: 'PP4' because the patients' phenotypes and family histories are highly specific for VHL disease.",Patient,NM_000551.3:c.533T>G,,NM_000551.3:c.533T>G,,,NG_008212.3:g.13222T>G,LRG_322:g.13222T>G,LRG_322t1:c.533T>G,NP_000542.1(LRG_322p1):p.(Leu178Arg),NC_000003.11:g.10191540T>G,3,10191540,.,T,G,NC_000003.12:g.10149856T>G,3,10149856,.,T,G,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,24986515,263,No,c.263G>A,NM_000551.3,p.Trp88*,W88* (c.263G>A),stop_gained,11,No,,HP:0010797,"(Ning et al., 2014)",E36Y0M; LK36Y0M,F,Chinese,"23 patients from 12 families diagnosed with hereditary VHL disease at the Peking University First Hospital Department of Urology were described as part of a broader study examining telomere length and anticipation. Family 11 involved two individuals with a c.263G>A mutation leading to a p.Trp88Stop change. The first individual, a female, presented with hemangioblastoma at 36. The second individual, a male, presented with renal cell carcinoma at 34 and pheochromocytoma at 38. ACMG Evidence Code: 'PP4' because the patients' phenotypes and family histories are highly specific for VHL disease. 'PM4' because of the protein length change caused by the heavily premature stop codon. 
",Patient,NM_000551.3:c.263G>A,,NM_000551.3:c.263G>A,,,NG_008212.3:g.5476G>A,LRG_322:g.5476G>A,LRG_322t1:c.263G>A,NP_000542.1(LRG_322p1):p.(Trp88Ter),NC_000003.11:g.10183794G>A,3,10183794,.,G,A,NC_000003.12:g.10142110G>A,3,10142110,.,G,A,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,24986515,263,No,c.263G>A,NM_000551.3,p.Trp88*,W88* (c.263G>A),stop_gained,11,No,,HP:0005584; HP:0002666,"(Ning et al., 2014)",E34Y0M; LK38Y0M,M,Chinese,"23 patients from 12 families diagnosed with hereditary VHL disease at the Peking University First Hospital Department of Urology were described as part of a broader study examining telomere length and anticipation. Family 11 involved two individuals with a c.263G>A mutation leading to a p.Trp88Stop change. The first individual, a female, presented with hemangioblastoma at 36. The second individual, a male, presented with renal cell carcinoma at 34 and pheochromocytoma at 38. ACMG Evidence Code: 'PP4' because the patients' phenotypes and family histories are highly specific for VHL disease. 'PM4' because of the protein length change caused by the heavily premature stop codon.",Patient,NM_000551.3:c.263G>A,,NM_000551.3:c.263G>A,,,NG_008212.3:g.5476G>A,LRG_322:g.5476G>A,LRG_322t1:c.263G>A,NP_000542.1(LRG_322p1):p.(Trp88Ter),NC_000003.11:g.10183794G>A,3,10183794,.,G,A,NC_000003.12:g.10142110G>A,3,10142110,.,G,A,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,24986515,292,No,c.292T>A,NM_000551.3,p.Tyr99Asn,Y99N (c.292T>A),missense_variant,14,No,,HP:0002666; HP:0010797; HP:0005584; HP:0001737,"(Ning et al., 2014)",E40Y0M; LK41Y0M,M,Chinese,"23 patients from 12 families diagnosed with hereditary VHL disease at the Peking University First Hospital Department of Urology were described as part of a broader study examining telomere length and anticipation. Family 14 involved one individual with a c.292T>A mutation leading to a p.Tyr99Asn change. This individual, a male, presented with pheochromocytoma at 40, hemangioblastoma at 40, renal cell carcinoma at 41, and pancreatic cysts at 41. ACMG Evidence Code: 'PP4' because the patients' phenotypes and family histories are highly specific for VHL disease.",Patient,NM_000551.3:c.292T>A,,NM_000551.3:c.292T>A,,,NG_008212.3:g.5505T>A,LRG_322:g.5505T>A,LRG_322t1:c.292T>A,NP_000542.1(LRG_322p1):p.(Tyr98Asn),NC_000003.11:g.10183823T>A,3,10183823,.,T,A,NC_000003.12:g.10142139T>A,3,10142139,.,T,A,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,24986515,481,No,c.481C>T,NM_000551.3,p.Arg161*,R161* (c.481C>T),stop_gained,15,No,,HP:0010797; HP:0005584; HP:0001737; HP:0009715; HP:0030393,"(Ning et al., 2014)",E29Y0M; LK36Y0M,M,Chinese,"23 patients from 12 families diagnosed with hereditary VHL disease at the Peking University First Hospital Department of Urology were described as part of a broader study examining telomere length and anticipation. Family 15 involved one individual with a c.481C>T mutation leading to a p.Arg161Stop change. This individual, a male, presented with hemangioblastoma at 29, renal cell carcinoma at 29, pancreatic cysts at 36, papillary cystadenoma of the epididymis at 29, and endolymphatic sac tumor at 33. ACMG Evidence Code: 'PP4' because the patients' phenotypes and family histories are highly specific for VHL disease. 'PM4' because of the protein length change caused by the heavily premature stop codon.",Patient,NM_000551.3:c.481C>T,,NM_000551.3:c.481C>T,,,NG_008212.3:g.13170C>T,LRG_322:g.13170C>T,LRG_322t1:c.481C>T,NP_000542.1(LRG_322p1):p.(Arg161Ter),NC_000003.11:g.10191488C>T,3,10191488,.,C,T,NC_000003.12:g.10149804C>T,3,10149804,.,C,T,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,24986515,500,No,c.500G>A,NM_000551.3,p.Arg167Gln,R167Q (c.500G>A),missense_variant,16,No,,HP:0010797; HP:0005584; HP:0002666,"(Ning et al., 2014)",E29Y0M; LK46Y0M,M,Chinese,"23 patients from 12 families diagnosed with hereditary VHL disease at the Peking University First Hospital Department of Urology were described as part of a broader study examining telomere length and anticipation. Family 16 involved one individual with a c.500G>A mutation leading to a p.Arg167Gln change. This individual, a male, presented with hemangioblastoma at 29, renal cell carcinomaa at 46, and pheochromocytoma at 46. ACMG Evidence Code: 'PP4' because the patients' phenotypes and family histories are highly specific for VHL disease.",Patient,NM_000551.3:c.500G>A,,NM_000551.3:c.500G>A,,,NG_008212.3:g.13189G>A,LRG_322:g.13189G>A,LRG_322t1:c.500G>A,NP_000542.1(LRG_322p1):p.(Arg167Gln),NC_000003.11:g.10191507G>A,3,10191507,.,G,A,NC_000003.12:g.10149823G>A,3,10149823,.,G,A,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,24986515,288,No,c.288_289insA,NM_000551.3,p.Pro97Thrfs*35,P97Tfs*35 (c.288insA),plus_1_frameshift_variant,18,No,,HP:0009711; HP:0010797; HP:0005584; HP:0009715,"(Ning et al., 2014)",E20Y0M; LK40Y0M,F,Chinese,"23 patients from 12 families diagnosed with hereditary VHL disease at the Peking University First Hospital Department of Urology were described as part of a broader study examining telomere length and anticipation. Family 18 involved one individual with a c.288insA mutation leading to a frameshift. The first individual, a female, presented with retinal capillary hemangioma at 20, hemangioblastoma at 29, renal cell carcinoma at 29, papillary cystadenoma of the epididymis at 40. The second individual, a male, presented with retinal capillary hemangioma at 34, renal cell carcinoma at 43, pheochromocytoma at 43. ACMG Evidence Code: 'PP4' because the patients' phenotypes and family histories are highly specific for VHL disease. 'PM4' because of the early frameshift mutation.",Patient,NM_000551.3:c.288_289insA,,NM_000551.3:c.288_289insA,,,NG_008212.3:g.5501_5502insA,LRG_322:g.5501_5502insA,LRG_322t1:c.288_289insA,NP_000542.1(LRG_322p1):p.(Pro97ThrfsTer35),NC_000003.11:g.10183819_10183820insA,3,10183819,.,G,GA,NC_000003.12:g.10142135_10142136insA,3,10142135,.,G,GA,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,24986515,288,No,c.288_289insA,NM_000551.3,p.Pro97Thrfs*35,P97Tfs*35 (c.288insA),plus_1_frameshift_variant,18,No,,HP:0009711; HP:0005584; HP:0002666,"(Ning et al., 2014)",E34Y0M; LK43Y0M,M,Chinese,"23 patients from 12 families diagnosed with hereditary VHL disease at the Peking University First Hospital Department of Urology were described as part of a broader study examining telomere length and anticipation. Family 18 involved one individual with a c.288insA mutation leading to a frameshift. The first individual, a female, presented with retinal capillary hemangioma at 20, hemangioblastoma at 29, renal cell carcinoma at 29, papillary cystadenoma of the epididymis at 40. The second individual, a male, presented with retinal capillary hemangioma at 34, renal cell carcinoma at 43, pheochromocytoma at 43. ACMG Evidence Code: 'PP4' because the patients' phenotypes and family histories are highly specific for VHL disease. 'PM4' because of the early frameshift mutation.",Patient,NM_000551.3:c.288_289insA,,NM_000551.3:c.288_289insA,,,NG_008212.3:g.5501_5502insA,LRG_322:g.5501_5502insA,LRG_322t1:c.288_289insA,NP_000542.1(LRG_322p1):p.(Pro97ThrfsTer35),NC_000003.11:g.10183819_10183820insA,3,10183819,.,G,GA,NC_000003.12:g.10142135_10142136insA,3,10142135,.,G,GA,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,29947576,239,No,c.239G>T,NM_000551.3,p.Ser80Ile,S80I (c.239G>T),missense_variant,1,No,,HP:0002666; HP:0002894; HP:0000107; HP:0006880,"(Yuan et al., 2018)",E29Y0M; LK43Y0M,F,,"A retrospective series of case reports details the clinical course of two members of a family testing positive for a c.239G>T VHL mutation elading to a p.Ser80Ile protein change. The first family member described is a 42 year old female, whoser presentations included bilateral pheochromocytoma at 29, neoplasm of the pancreas at 38, renal cysts at 42, and cerebellar hemangioblastoma at 43. Family history was positive for her two children. The second patient, the brother of the first patient, presented with bilateral pheochromocytoma at 38, cerebellar hemangioblastoma at 46, and renal cysts at 54. ACMG Code: 'PP4' because the presentations and family histories of the patients are highly specific for Von-Hippel Lindau syndrome. ",Patient,NM_000551.3:c.239G>T,,NM_000551.3:c.239G>T,,,NG_008212.3:g.5452G>T,LRG_322:g.5452G>T,LRG_322t1:c.239G>T,NP_000542.1(LRG_322p1):p.(Ser80Ile),NC_000003.11:g.10183770G>T,3,10183770,.,G,T,NC_000003.12:g.10142086G>T,3,10142086,.,G,T,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,29947576,239,No,c.239G>T,NM_000551.3,p.Ser80Ile,S80I (c.239G>T),missense_variant,1,No,,HP:0002666; HP:0006880; HP:0000107,"(Yuan et al., 2018)",E38Y0M; LK54Y0M,M,,"A retrospective series of case reports details the clinical course of two members of a family testing positive for a c.239G>T VHL mutation elading to a p.Ser80Ile protein change. The first family member described is a 42 year old female, whoser presentations included bilateral pheochromocytoma at 29, neoplasm of the pancreas at 38, renal cysts at 42, and cerebellar hemangioblastoma at 43. Family history was positive for her two children. The second patient, the brother of the first patient, presented with bilateral pheochromocytoma at 38, cerebellar hemangioblastoma at 46, and renal cysts at 54. ACMG Code: 'PP4' because the presentations and family histories of the patients are highly specific for Von-Hippel Lindau syndrome. ",Patient,NM_000551.3:c.239G>T,,NM_000551.3:c.239G>T,,,NG_008212.3:g.5452G>T,LRG_322:g.5452G>T,LRG_322t1:c.239G>T,NP_000542.1(LRG_322p1):p.(Ser80Ile),NC_000003.11:g.10183770G>T,3,10183770,.,G,T,NC_000003.12:g.10142086G>T,3,10142086,.,G,T,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,29947576,232,No,c.232A>T,NM_000551.3,p.Asn78Tyr,N78Y (c.232A>T),missense_variant,2,No,,HP:0002894; HP:0000107,"(Yuan et al., 2018)",LK50Y0M,F,,"A retrospective series of case reports details the clinical course of a 50 year old female with a c.232A>T mutaiton in the VHL gene, leading to a p.Asn78Tyr protein change. Her presentations included neoplasm of the pancreas, renal cysts, and unidentified back tumor. ACMG Code: 'PP4' because the presentations and family histories of the patients are highly specific for Von-Hippel Lindau syndrome. ",Patient,NM_000551.3:c.232A>T,,NM_000551.3:c.232A>T,,,NG_008212.3:g.5445A>T,LRG_322:g.5445A>T,LRG_322t1:c.232A>T,NP_000542.1(LRG_322p1):p.(Asn78Tyr),NC_000003.11:g.10183763A>T,3,10183763,.,A,T,NC_000003.12:g.10142079A>T,3,10142079,.,A,T,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,31016171,382,No,c.382C>T,NM_000551.3,p.Leu128Phe,L128F (c.382C>T),missense_variant,1,No,,HP:0002666,"(Pradham et al., 2019)",E11Y0M,F,Indian,"Case report details an 11 year old female and 7 year old male (cousins) presenting with, respectively, unilateral and bilateral pheochromocytomas. Genetic testing on peripheral blood indicating a c.382T>C frameshift mutation. ACMG Evidence Codes:  'PP4' because the pattern of presentations observed is highly specific for VHL disease.",Patient,NM_000551.3:c.382C>T,,NM_000551.3:c.382C>T,,,NG_008212.3:g.9921C>T,LRG_322:g.9921C>T,LRG_322t1:c.382C>T,NP_000542.1(LRG_322p1):p.(Leu128Phe),NC_000003.11:g.10188239C>T,3,10188239,.,C,T,NC_000003.12:g.10146555C>T,3,10146555,.,C,T,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,31016171,382,No,c.382C>T,NM_000551.3,p.Leu128Phe,L128F (c.382C>T),missense_variant,1,No,,HP:0002666,"(Pradham et al., 2019)",E7Y0M,M,Indian,"Case report details an 11 year old female and 7 year old male (cousins) presenting with, respectively, unilateral and bilateral pheochromocytomas. Genetic testing on peripheral blood indicating a c.382T>C frameshift mutation. ACMG Evidence Codes:  'PP4' because the pattern of presentations observed is highly specific for VHL disease.",Patient,NM_000551.3:c.382C>T,,NM_000551.3:c.382C>T,,,NG_008212.3:g.9921C>T,LRG_322:g.9921C>T,LRG_322t1:c.382C>T,NP_000542.1(LRG_322p1):p.(Leu128Phe),NC_000003.11:g.10188239C>T,3,10188239,.,C,T,NC_000003.12:g.10146555C>T,3,10146555,.,C,T,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,31016171,277,No,c.277G>C,NM_000551.3,p.Gly93Arg,G93R (c.277G>C),missense_variant,2,No,,HP:0002666; HP:0010797; HP:0001737; HP:0000107 ,"(Pradham et al., 2019)",E16Y0M,M,Indian,"Case report details a 16 year old male presenting with pheochromocytoma, CNS hemangioblastoma, pancreatic cysts, and renal cysts. Genetic testing of peripheral blood reveals a c.277G>C mutation. ACMG Evidence Codes:  'PP4' because the pattern of presentations observed is highly specific for VHL disease.",Patient,NM_000551.3:c.277G>C,,NM_000551.3:c.277G>C,,,NG_008212.3:g.5490G>C,LRG_322:g.5490G>C,LRG_322t1:c.277G>C,NP_000542.1(LRG_322p1):p.(Gly93Arg),NC_000003.11:g.10183808G>C,3,10183808,.,G,C,NC_000003.12:g.10142124G>C,3,10142124,.,G,C,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,31016171,500,No,c.500G>A,NM_000551.3,p.Arg167Gln,R167Q (c.500G>A),missense_variant,3,No,,HP:0002666; HP:0010797; HP:0030405,"(Pradham et al., 2019)",E26Y0M,M,Indian,"Case report details a 26 year old male presenting with unilateral pheochromocytoma, pancreatic neuroendocrine tumor, and CNS hemangioblastoma. Mutation analysis reveals a c.G500>A change. ACMG code ""PS1"", as this is the same mutation as a previously described pathogenic variant. ACMG Evidence Codes:  'PP4' because the pattern of presentations observed is highly specific for VHL disease.",Patient,NM_000551.3:c.500G>A,,NM_000551.3:c.500G>A,,,NG_008212.3:g.13189G>A,LRG_322:g.13189G>A,LRG_322t1:c.500G>A,NP_000542.1(LRG_322p1):p.(Arg167Gln),NC_000003.11:g.10191507G>A,3,10191507,.,G,A,NC_000003.12:g.10149823G>A,3,10149823,.,G,A,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,21685785,313,No,c.313A>C,NM_000551.3,p.Thr105Pro,T105P (c.313A>C),missense_variant,1,No,,HP:0010797; HP:0001737; HP:0000107,"(Pruksakorn et al., 2011)",E27Y0M,M,Thai,"A case report details a 27 year old male presenting with spinal hemangioblastoma, pancreatic cysts, and kidney cysts. Genetic testing of unclear nature revealed the presence of a c.313A>C mutation, with a predicted p.Thr105Pro change. ACMG Evidence Codes:  'PP4' because the pattern of presentations observed is highly specific for VHL disease.",Patient,NM_000551.3:c.313A>C,,NM_000551.3:c.313A>C,,,NG_008212.3:g.5526A>C,LRG_322:g.5526A>C,LRG_322t1:c.313A>C,NP_000542.1(LRG_322p1):p.(Thr105Pro),NC_000003.11:g.10183844A>C,3,10183844,.,A,C,NC_000003.12:g.10142160A>C,3,10142160,.,A,C,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,16572651,256,No,c.256C>T,NM_000551.3,p.Pro86Ser,P86S (c.256C>T),missense_variant,6,No,,HP:0006880; HP:0000107; HP:0005584,"(Rasmussen et al., 2006)",LK30Y0M,unknown,Mexican,"Patients presenting with cerebellar hemangioblastomas at the Mexican National institute of Neurology and Neurosurgery to were prospectively enrolled alongside family members, resulting in 84 patients in 7 families with VHL mutations, and subjected to peripheral blood draw and PCR-based mutation screening, as well as full clinical screening for symptomatic individuals. One patient had a c.256C>T mutation identified, leading to a P86S missense mutation. This patient presented at 30 with a history of recurrent cerebellar hemangioblastoma, kidney cysts, and bilateral renal cell carcinoma. Family history was not indicated. ACMG Evidence Codes: 'PP4' because the patients' phenotypes or family histories are highly specific for VHL disease.",Family,NM_000551.3:c.256C>T,,NM_000551.3:c.256C>T,,,NG_008212.3:g.5469C>T,LRG_322:g.5469C>T,LRG_322t1:c.256C>T,NP_000542.1(LRG_322p1):p.(Pro86Ser),NC_000003.11:g.10183787C>T,3,10183787,.,C,T,NC_000003.12:g.10142103C>T,3,10142103,.,C,T,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,16572651,481,No,c.481C>T,NM_000551.3,p.Arg161*,R161* (c.481C>T),missense_variant,5,No,,HP:0006880; HP:0001737; HP:0000107,"(Rasmussen et al., 2006)",LK32Y0M,unknown,Mexican,"Patients presenting with cerebellar hemangioblastomas at the Mexican National institute of Neurology and Neurosurgery to were prospectively enrolled alongside family members, resulting in 84 patients in 7 families with VHL mutations, and subjected to peripheral blood draw and PCR-based mutation screening, as well as full clinical screening for symptomatic individuals. One patient had a c.256C>T mutation identified, leading to a P86S missense mutation. This patient presented at 30 with a history of recurrent cerebellar hemangioblastoma, kidney cysts, and bilateral renal cell carcinoma. Family history was not indicated. ACMG Evidence Codes: 'PP4' because the patients' phenotypes or family histories are highly specific for VHL disease.",Family,NM_000551.3:c.481C>T,,NM_000551.3:c.481C>T,,,NG_008212.3:g.13170C>T,LRG_322:g.13170C>T,LRG_322t1:c.481C>T,NP_000542.1(LRG_322p1):p.(Arg161Ter),NC_000003.11:g.10191488C>T,3,10191488,.,C,T,NC_000003.12:g.10149804C>T,3,10149804,.,C,T,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,16572651,362,No,c.362A>G,NM_000551.3,p.Asp121Gly,D121G (c.362A>G),missense_variant,4,No,,HP:0006880; HP:0009711; HP:0001737; HP:0000107; HP:0005584; HP:0002666,"(Rasmussen et al., 2006)",LK29Y0M,unknown,Mexican,"Patients presenting with cerebellar hemangioblastomas at the Mexican National institute of Neurology and Neurosurgery to were prospectively enrolled alongside family members, resulting in 84 patients in 7 families with VHL mutations, and subjected to peripheral blood draw and PCR-based mutation screening, as well as full clinical screening for symptomatic individuals. One patient had a c.256C>T mutation identified, leading to a P86S missense mutation. This patient presented at 30 with a history of recurrent cerebellar hemangioblastoma, kidney cysts, and bilateral renal cell carcinoma. Family history was not indicated. ACMG Evidence Codes: 'PP4' because the patients' phenotypes or family histories are highly specific for VHL disease.",Family,NM_000551.3:c.362A>G,,NM_000551.3:c.362A>G,,,NG_008212.3:g.9901A>G,LRG_322:g.9901A>G,LRG_322t1:c.362A>G,NP_000542.1(LRG_322p1):p.(Asp121Gly),NC_000003.11:g.10188219A>G,3,10188219,.,A,G,NC_000003.12:g.10146535A>G,3,10146535,.,A,G,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,16572651,225,No,c.225_227del,NM_000551.3,Phe76del,F76* (c.225del3bp),deletion,1,No,,HP:0006880; HP:0009713; HP:0000107,"(Rasmussen et al., 2006)",LK34Y0M,unknown,Mexican,"Patients presenting with cerebellar hemangioblastomas at the Mexican National institute of Neurology and Neurosurgery to were prospectively enrolled alongside family members, resulting in 84 patients in 7 families with VHL mutations, and subjected to peripheral blood draw and VHL exon / promotor sqeuencing, as well as full clinical screening for symptomatic individuals. for all symptomatic individuals. 3 members of family ""A"" tested positive for a DelPhe76 mutation. One individual presented at 34 with 2 cerebellar hemangioblastomas, 1 spinal hemangioblastoma, and multiple kidney cysts. Another presented at 35 with 2 cerebellar hemangioblastomas. The third presented at 29 with >3 cerebellar hemangioblastomas. ACMG Evidence Codes:  'PM4' because it is a 3bp deletion that causes a protein length change but not a frameshift due to the deletion of exactly 3 base pairs, 'PP4' because the patients' phenotypes or family histories are highly specific for VHL disease. ",Family,NM_000551.3:c.225_227del,NM_000551.3:c.225_227del automapped to NM_000551.3:c.227_229delTCT,NM_000551.3:c.227_229del,,,NG_008212.3:g.5440_5442del,LRG_322:g.5440_5442del,LRG_322t1:c.227_229del,NP_000542.1(LRG_322p1):p.(Phe76del),NC_000003.11:g.10183758_10183760del,3,10183754,.,ATCT,A,NC_000003.12:g.10142074_10142076del,3,10142070,.,ATCT,A,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,16572651,225,No,c.225_227del,NM_000551.3,Phe76del,F76* (c.225del3bp),deletion,1,No,,HP:0006880,"(Rasmussen et al., 2006)",LK35Y0M,unknown,Mexican,"Patients presenting with cerebellar hemangioblastomas at the Mexican National institute of Neurology and Neurosurgery to were prospectively enrolled alongside family members, resulting in 84 patients in 7 families with VHL mutations, and subjected to peripheral blood draw and VHL exon / promotor sqeuencing, as well as full clinical screening for symptomatic individuals. for all symptomatic individuals. 3 members of family ""A"" tested positive for a DelPhe76 mutation. One individual presented at 34 with 2 cerebellar hemangioblastomas, 1 spinal hemangioblastoma, and multiple kidney cysts. Another presented at 35 with 2 cerebellar hemangioblastomas. The third presented at 29 with >3 cerebellar hemangioblastomas. ACMG Evidence Codes:  'PM4' because it is a 3bp deletion that causes a protein length change but not a frameshift due to the deletion of exactly 3 base pairs, 'PP4' because the patients' phenotypes or family histories are highly specific for VHL disease. ",Family,NM_000551.3:c.225_227del,NM_000551.3:c.225_227del automapped to NM_000551.3:c.227_229delTCT,NM_000551.3:c.227_229del,,,NG_008212.3:g.5440_5442del,LRG_322:g.5440_5442del,LRG_322t1:c.227_229del,NP_000542.1(LRG_322p1):p.(Phe76del),NC_000003.11:g.10183758_10183760del,3,10183754,.,ATCT,A,NC_000003.12:g.10142074_10142076del,3,10142070,.,ATCT,A,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,16572651,225,No,c.225_227del,NM_000551.3,Phe76del,F76* (c.225del3bp),deletion,1,No,,HP:0006880,"(Rasmussen et al., 2006)",LK29Y0M,unknown,Mexican,"Patients presenting with cerebellar hemangioblastomas at the Mexican National institute of Neurology and Neurosurgery to were prospectively enrolled alongside family members, resulting in 84 patients in 7 families with VHL mutations, and subjected to peripheral blood draw and VHL exon / promotor sqeuencing, as well as full clinical screening for symptomatic individuals. for all symptomatic individuals. 3 members of family ""A"" tested positive for a DelPhe76 mutation. One individual presented at 34 with 2 cerebellar hemangioblastomas, 1 spinal hemangioblastoma, and multiple kidney cysts. Another presented at 35 with 2 cerebellar hemangioblastomas. The third presented at 29 with >3 cerebellar hemangioblastomas. ACMG Evidence Codes:  'PM4' because it is a 3bp deletion that causes a protein length change but not a frameshift due to the deletion of exactly 3 base pairs, 'PP4' because the patients' phenotypes or family histories are highly specific for VHL disease. ",Family,NM_000551.3:c.225_227del,NM_000551.3:c.225_227del automapped to NM_000551.3:c.227_229delTCT,NM_000551.3:c.227_229del,,,NG_008212.3:g.5440_5442del,LRG_322:g.5440_5442del,LRG_322t1:c.227_229del,NP_000542.1(LRG_322p1):p.(Phe76del),NC_000003.11:g.10183758_10183760del,3,10183754,.,ATCT,A,NC_000003.12:g.10142074_10142076del,3,10142070,.,ATCT,A,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,16572651,298,No,c.298dupA,NM_000551.3,p.Thr100Asnfs*32,T100Nfs*32 (c.298dupA),plus_1_frameshift_variant,2,No,,HP:0006880; HP:0009711,"(Rasmussen et al., 2006)",LK44Y0M,unknown,Mexican,"Patients presenting with cerebellar hemangioblastomas at the Mexican National institute of Neurology and Neurosurgery to were prospectively enrolled alongside family members, resulting in 84 patients in 7 families with VHL mutations, and subjected to peripheral blood draw and PCR-based mutation screening, as well as full clinical screening for symptomatic individuals.. 19 individuals across two families (Family ""B"" and Family ""C"") presented with a c.298dupA mutation, leading to a frameshift. Among these individuals, 2 in Family B and 6 in Family C were asymptomatic at the time of screening (ages 7, 2, 17, 12, 13, 20, 29, and 9). 
 
 Of the 4 symptomatic individuals in Family B, one presented at 44 with cerebellar hemangioblastoma and bilateral retinal angiomas; one presented at 16 with 4 cerebellar hemangioblastomas, 1 bulbar hemangioblastoma, 1 spinal hemangioblastoma, bilateral retinal angiomas, pancreatic cysts, and kidney cysts; one presented at age 26 with cerebellar hemangioblastoma, bilateral retinal angiomas, pancreatic cysts, kidney cysts, and renal cell carcinoma; and one presented at 28 with 1 cerebellar hemangioblastoma. 
 
 Of the 7 symptomatic individuals in Family C, one presented at 45 with cerebellar hemangioblastoma, pancreatic cysts, kidney cysts, and renal cell carcinoma; one presented at age 21 with epididymal cystadenoma; one presented at 36 with 2 cerebellar hemangioblastomas, pancreatic cysts, kidney cysts, hepatic cysts, adrenal cysts, and bilateral renal cell carcinomas; one presented at 20 with spinal hemangioblastoma, pancreatic cysts, and kidney cysts; one presented at 13 with 2 spinal hemangioblastomas, one presented at 13 with cerebellar hemangioblastoma, one presented at 30 with cerebellar hemangioblastoma, pancreatic cysts, and kidney cysts. ACMG Evidence Codes: 'PP4' because the patients' phenotypes or family histories are highly specific for VHL disease.",Family,NM_000551.3:c.298dupA,,NM_000551.3:c.298dup,,,NG_008212.3:g.5511dup,LRG_322:g.5511dup,LRG_322t1:c.298dup,NP_000542.1(LRG_322p1):p.(Thr100AsnfsTer32),NC_000003.11:g.10183829dup,3,10183827,.,C,CA,NC_000003.12:g.10142145dup,3,10142143,.,C,CA,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,16572651,298,No,c.298dupA,NM_000551.3,p.Thr100Asnfs*32,T100Nfs*32 (c.298dupA),plus_1_frameshift_variant,2,No,,HP:0006880; HP:0010797; HP:0009713; HP:0009711; HP:0001737; HP:0000107,"(Rasmussen et al., 2006)",LK16Y0M,unknown,Mexican,"Patients presenting with cerebellar hemangioblastomas at the Mexican National institute of Neurology and Neurosurgery to were prospectively enrolled alongside family members, resulting in 84 patients in 7 families with VHL mutations, and subjected to peripheral blood draw and PCR-based mutation screening, as well as full clinical screening for symptomatic individuals.. 19 individuals across two families (Family ""B"" and Family ""C"") presented with a c.298dupA mutation, leading to a frameshift. Among these individuals, 2 in Family B and 6 in Family C were asymptomatic at the time of screening (ages 7, 2, 17, 12, 13, 20, 29, and 9). 
 
 Of the 4 symptomatic individuals in Family B, one presented at 44 with cerebellar hemangioblastoma and bilateral retinal angiomas; one presented at 16 with 4 cerebellar hemangioblastomas, 1 bulbar hemangioblastoma, 1 spinal hemangioblastoma, bilateral retinal angiomas, pancreatic cysts, and kidney cysts; one presented at age 26 with cerebellar hemangioblastoma, bilateral retinal angiomas, pancreatic cysts, kidney cysts, and renal cell carcinoma; and one presented at 28 with 1 cerebellar hemangioblastoma. 
 
 Of the 7 symptomatic individuals in Family C, one presented at 45 with cerebellar hemangioblastoma, pancreatic cysts, kidney cysts, and renal cell carcinoma; one presented at age 21 with epididymal cystadenoma; one presented at 36 with 2 cerebellar hemangioblastomas, pancreatic cysts, kidney cysts, hepatic cysts, adrenal cysts, and bilateral renal cell carcinomas; one presented at 20 with spinal hemangioblastoma, pancreatic cysts, and kidney cysts; one presented at 13 with 2 spinal hemangioblastomas, one presented at 13 with cerebellar hemangioblastoma, one presented at 30 with cerebellar hemangioblastoma, pancreatic cysts, and kidney cysts. ACMG Evidence Codes: 'PP4' because the patients' phenotypes or family histories are highly specific for VHL disease.",Family,NM_000551.3:c.298dupA,,NM_000551.3:c.298dup,,,NG_008212.3:g.5511dup,LRG_322:g.5511dup,LRG_322t1:c.298dup,NP_000542.1(LRG_322p1):p.(Thr100AsnfsTer32),NC_000003.11:g.10183829dup,3,10183827,.,C,CA,NC_000003.12:g.10142145dup,3,10142143,.,C,CA,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,16572651,298,No,c.298dupA,NM_000551.3,p.Thr100Asnfs*32,T100Nfs*32 (c.298dupA),plus_1_frameshift_variant,2,No,,HP:0006880; HP:0009711; HP:0001737; HP:0000107;H P:0005584,"(Rasmussen et al., 2006)",LK26Y0M,unknown,Mexican,"Patients presenting with cerebellar hemangioblastomas at the Mexican National institute of Neurology and Neurosurgery to were prospectively enrolled alongside family members, resulting in 84 patients in 7 families with VHL mutations, and subjected to peripheral blood draw and PCR-based mutation screening, as well as full clinical screening for symptomatic individuals.. 19 individuals across two families (Family ""B"" and Family ""C"") presented with a c.298dupA mutation, leading to a frameshift. Among these individuals, 2 in Family B and 6 in Family C were asymptomatic at the time of screening (ages 7, 2, 17, 12, 13, 20, 29, and 9). 
 
 Of the 4 symptomatic individuals in Family B, one presented at 44 with cerebellar hemangioblastoma and bilateral retinal angiomas; one presented at 16 with 4 cerebellar hemangioblastomas, 1 bulbar hemangioblastoma, 1 spinal hemangioblastoma, bilateral retinal angiomas, pancreatic cysts, and kidney cysts; one presented at age 26 with cerebellar hemangioblastoma, bilateral retinal angiomas, pancreatic cysts, kidney cysts, and renal cell carcinoma; and one presented at 28 with 1 cerebellar hemangioblastoma. 
 
 Of the 7 symptomatic individuals in Family C, one presented at 45 with cerebellar hemangioblastoma, pancreatic cysts, kidney cysts, and renal cell carcinoma; one presented at age 21 with epididymal cystadenoma; one presented at 36 with 2 cerebellar hemangioblastomas, pancreatic cysts, kidney cysts, hepatic cysts, adrenal cysts, and bilateral renal cell carcinomas; one presented at 20 with spinal hemangioblastoma, pancreatic cysts, and kidney cysts; one presented at 13 with 2 spinal hemangioblastomas, one presented at 13 with cerebellar hemangioblastoma, one presented at 30 with cerebellar hemangioblastoma, pancreatic cysts, and kidney cysts. ACMG Evidence Codes: 'PP4' because the patients' phenotypes or family histories are highly specific for VHL disease.",Family,NM_000551.3:c.298dupA,,NM_000551.3:c.298dup,,,NG_008212.3:g.5511dup,LRG_322:g.5511dup,LRG_322t1:c.298dup,NP_000542.1(LRG_322p1):p.(Thr100AsnfsTer32),NC_000003.11:g.10183829dup,3,10183827,.,C,CA,NC_000003.12:g.10142145dup,3,10142143,.,C,CA,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,16572651,298,No,c.298dupA,NM_000551.3,p.Thr100Asnfs*32,T100Nfs*32 (c.298dupA),plus_1_frameshift_variant,2,No,,HP:0006880,"(Rasmussen et al., 2006)",LK28Y0M,unknown,Mexican,"Patients presenting with cerebellar hemangioblastomas at the Mexican National institute of Neurology and Neurosurgery to were prospectively enrolled alongside family members, resulting in 84 patients in 7 families with VHL mutations, and subjected to peripheral blood draw and PCR-based mutation screening, as well as full clinical screening for symptomatic individuals.. 19 individuals across two families (Family ""B"" and Family ""C"") presented with a c.298dupA mutation, leading to a frameshift. Among these individuals, 2 in Family B and 6 in Family C were asymptomatic at the time of screening (ages 7, 2, 17, 12, 13, 20, 29, and 9). 
 
 Of the 4 symptomatic individuals in Family B, one presented at 44 with cerebellar hemangioblastoma and bilateral retinal angiomas; one presented at 16 with 4 cerebellar hemangioblastomas, 1 bulbar hemangioblastoma, 1 spinal hemangioblastoma, bilateral retinal angiomas, pancreatic cysts, and kidney cysts; one presented at age 26 with cerebellar hemangioblastoma, bilateral retinal angiomas, pancreatic cysts, kidney cysts, and renal cell carcinoma; and one presented at 28 with 1 cerebellar hemangioblastoma. 
 
 Of the 7 symptomatic individuals in Family C, one presented at 45 with cerebellar hemangioblastoma, pancreatic cysts, kidney cysts, and renal cell carcinoma; one presented at age 21 with epididymal cystadenoma; one presented at 36 with 2 cerebellar hemangioblastomas, pancreatic cysts, kidney cysts, hepatic cysts, adrenal cysts, and bilateral renal cell carcinomas; one presented at 20 with spinal hemangioblastoma, pancreatic cysts, and kidney cysts; one presented at 13 with 2 spinal hemangioblastomas, one presented at 13 with cerebellar hemangioblastoma, one presented at 30 with cerebellar hemangioblastoma, pancreatic cysts, and kidney cysts. ACMG Evidence Codes: 'PP4' because the patients' phenotypes or family histories are highly specific for VHL disease.",Family,NM_000551.3:c.298dupA,,NM_000551.3:c.298dup,,,NG_008212.3:g.5511dup,LRG_322:g.5511dup,LRG_322t1:c.298dup,NP_000542.1(LRG_322p1):p.(Thr100AsnfsTer32),NC_000003.11:g.10183829dup,3,10183827,.,C,CA,NC_000003.12:g.10142145dup,3,10142143,.,C,CA,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,16572651,298,No,c.298dupA,NM_000551.3,p.Thr100Asnfs*32,T100Nfs*32 (c.298dupA),plus_1_frameshift_variant,2,No,,Unknown,"(Rasmussen et al., 2006)",LK7Y0M,unknown,Mexican,"Patients presenting with cerebellar hemangioblastomas at the Mexican National institute of Neurology and Neurosurgery to were prospectively enrolled alongside family members, resulting in 84 patients in 7 families with VHL mutations, and subjected to peripheral blood draw and PCR-based mutation screening, as well as full clinical screening for symptomatic individuals.. 19 individuals across two families (Family ""B"" and Family ""C"") presented with a c.298dupA mutation, leading to a frameshift. Among these individuals, 2 in Family B and 6 in Family C were asymptomatic at the time of screening (ages 7, 2, 17, 12, 13, 20, 29, and 9). 
 
 Of the 4 symptomatic individuals in Family B, one presented at 44 with cerebellar hemangioblastoma and bilateral retinal angiomas; one presented at 16 with 4 cerebellar hemangioblastomas, 1 bulbar hemangioblastoma, 1 spinal hemangioblastoma, bilateral retinal angiomas, pancreatic cysts, and kidney cysts; one presented at age 26 with cerebellar hemangioblastoma, bilateral retinal angiomas, pancreatic cysts, kidney cysts, and renal cell carcinoma; and one presented at 28 with 1 cerebellar hemangioblastoma. 
 
 Of the 7 symptomatic individuals in Family C, one presented at 45 with cerebellar hemangioblastoma, pancreatic cysts, kidney cysts, and renal cell carcinoma; one presented at age 21 with epididymal cystadenoma; one presented at 36 with 2 cerebellar hemangioblastomas, pancreatic cysts, kidney cysts, hepatic cysts, adrenal cysts, and bilateral renal cell carcinomas; one presented at 20 with spinal hemangioblastoma, pancreatic cysts, and kidney cysts; one presented at 13 with 2 spinal hemangioblastomas, one presented at 13 with cerebellar hemangioblastoma, one presented at 30 with cerebellar hemangioblastoma, pancreatic cysts, and kidney cysts. ACMG Evidence Codes: 'PP4' because the patients' phenotypes or family histories are highly specific for VHL disease.",Family,NM_000551.3:c.298dupA,,NM_000551.3:c.298dup,,,NG_008212.3:g.5511dup,LRG_322:g.5511dup,LRG_322t1:c.298dup,NP_000542.1(LRG_322p1):p.(Thr100AsnfsTer32),NC_000003.11:g.10183829dup,3,10183827,.,C,CA,NC_000003.12:g.10142145dup,3,10142143,.,C,CA,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,16572651,298,No,c.298dupA,NM_000551.3,p.Thr100Asnfs*32,T100Nfs*32 (c.298dupA),plus_1_frameshift_variant,2,No,,Unknown,"(Rasmussen et al., 2006)",LK2Y0M,unknown,Mexican,"Patients presenting with cerebellar hemangioblastomas at the Mexican National institute of Neurology and Neurosurgery to were prospectively enrolled alongside family members, resulting in 84 patients in 7 families with VHL mutations, and subjected to peripheral blood draw and PCR-based mutation screening, as well as full clinical screening for symptomatic individuals.. 19 individuals across two families (Family ""B"" and Family ""C"") presented with a c.298dupA mutation, leading to a frameshift. Among these individuals, 2 in Family B and 6 in Family C were asymptomatic at the time of screening (ages 7, 2, 17, 12, 13, 20, 29, and 9). 
 
 Of the 4 symptomatic individuals in Family B, one presented at 44 with cerebellar hemangioblastoma and bilateral retinal angiomas; one presented at 16 with 4 cerebellar hemangioblastomas, 1 bulbar hemangioblastoma, 1 spinal hemangioblastoma, bilateral retinal angiomas, pancreatic cysts, and kidney cysts; one presented at age 26 with cerebellar hemangioblastoma, bilateral retinal angiomas, pancreatic cysts, kidney cysts, and renal cell carcinoma; and one presented at 28 with 1 cerebellar hemangioblastoma. 
 
 Of the 7 symptomatic individuals in Family C, one presented at 45 with cerebellar hemangioblastoma, pancreatic cysts, kidney cysts, and renal cell carcinoma; one presented at age 21 with epididymal cystadenoma; one presented at 36 with 2 cerebellar hemangioblastomas, pancreatic cysts, kidney cysts, hepatic cysts, adrenal cysts, and bilateral renal cell carcinomas; one presented at 20 with spinal hemangioblastoma, pancreatic cysts, and kidney cysts; one presented at 13 with 2 spinal hemangioblastomas, one presented at 13 with cerebellar hemangioblastoma, one presented at 30 with cerebellar hemangioblastoma, pancreatic cysts, and kidney cysts. ACMG Evidence Codes: 'PP4' because the patients' phenotypes or family histories are highly specific for VHL disease.",Family,NM_000551.3:c.298dupA,,NM_000551.3:c.298dup,,,NG_008212.3:g.5511dup,LRG_322:g.5511dup,LRG_322t1:c.298dup,NP_000542.1(LRG_322p1):p.(Thr100AsnfsTer32),NC_000003.11:g.10183829dup,3,10183827,.,C,CA,NC_000003.12:g.10142145dup,3,10142143,.,C,CA,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,16572651,298,No,c.298dupA,NM_000551.3,p.Thr100Asnfs*32,T100Nfs*32 (c.298dupA),plus_1_frameshift_variant,3,No,,HP:0006880; HP:0001737; HP:0000107; HP:0005584,"(Rasmussen et al., 2006)",LK45Y0M,unknown,Mexican,"Patients presenting with cerebellar hemangioblastomas at the Mexican National institute of Neurology and Neurosurgery to were prospectively enrolled alongside family members, resulting in 84 patients in 7 families with VHL mutations, and subjected to peripheral blood draw and PCR-based mutation screening, as well as full clinical screening for symptomatic individuals.. 19 individuals across two families (Family ""B"" and Family ""C"") presented with a c.298dupA mutation, leading to a frameshift. Among these individuals, 2 in Family B and 6 in Family C were asymptomatic at the time of screening (ages 7, 2, 17, 12, 13, 20, 29, and 9). 
 
 Of the 4 symptomatic individuals in Family B, one presented at 44 with cerebellar hemangioblastoma and bilateral retinal angiomas; one presented at 16 with 4 cerebellar hemangioblastomas, 1 bulbar hemangioblastoma, 1 spinal hemangioblastoma, bilateral retinal angiomas, pancreatic cysts, and kidney cysts; one presented at age 26 with cerebellar hemangioblastoma, bilateral retinal angiomas, pancreatic cysts, kidney cysts, and renal cell carcinoma; and one presented at 28 with 1 cerebellar hemangioblastoma. 
 
 Of the 7 symptomatic individuals in Family C, one presented at 45 with cerebellar hemangioblastoma, pancreatic cysts, kidney cysts, and renal cell carcinoma; one presented at age 21 with epididymal cystadenoma; one presented at 36 with 2 cerebellar hemangioblastomas, pancreatic cysts, kidney cysts, hepatic cysts, adrenal cysts, and bilateral renal cell carcinomas; one presented at 20 with spinal hemangioblastoma, pancreatic cysts, and kidney cysts; one presented at 13 with 2 spinal hemangioblastomas, one presented at 13 with cerebellar hemangioblastoma, one presented at 30 with cerebellar hemangioblastoma, pancreatic cysts, and kidney cysts. ACMG Evidence Codes: 'PP4' because the patients' phenotypes or family histories are highly specific for VHL disease.",Family,NM_000551.3:c.298dupA,,NM_000551.3:c.298dup,,,NG_008212.3:g.5511dup,LRG_322:g.5511dup,LRG_322t1:c.298dup,NP_000542.1(LRG_322p1):p.(Thr100AsnfsTer32),NC_000003.11:g.10183829dup,3,10183827,.,C,CA,NC_000003.12:g.10142145dup,3,10142143,.,C,CA,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,16572651,298,No,c.298dupA,NM_000551.3,p.Thr100Asnfs*32,T100Nfs*32 (c.298dupA),plus_1_frameshift_variant,3,No,,HP:0009715,"(Rasmussen et al., 2006)",LK21Y0M,unknown,Mexican,"Patients presenting with cerebellar hemangioblastomas at the Mexican National institute of Neurology and Neurosurgery to were prospectively enrolled alongside family members, resulting in 84 patients in 7 families with VHL mutations, and subjected to peripheral blood draw and PCR-based mutation screening, as well as full clinical screening for symptomatic individuals.. 19 individuals across two families (Family ""B"" and Family ""C"") presented with a c.298dupA mutation, leading to a frameshift. Among these individuals, 2 in Family B and 6 in Family C were asymptomatic at the time of screening (ages 7, 2, 17, 12, 13, 20, 29, and 9). 
 
 Of the 4 symptomatic individuals in Family B, one presented at 44 with cerebellar hemangioblastoma and bilateral retinal angiomas; one presented at 16 with 4 cerebellar hemangioblastomas, 1 bulbar hemangioblastoma, 1 spinal hemangioblastoma, bilateral retinal angiomas, pancreatic cysts, and kidney cysts; one presented at age 26 with cerebellar hemangioblastoma, bilateral retinal angiomas, pancreatic cysts, kidney cysts, and renal cell carcinoma; and one presented at 28 with 1 cerebellar hemangioblastoma. 
 
 Of the 7 symptomatic individuals in Family C, one presented at 45 with cerebellar hemangioblastoma, pancreatic cysts, kidney cysts, and renal cell carcinoma; one presented at age 21 with epididymal cystadenoma; one presented at 36 with 2 cerebellar hemangioblastomas, pancreatic cysts, kidney cysts, hepatic cysts, adrenal cysts, and bilateral renal cell carcinomas; one presented at 20 with spinal hemangioblastoma, pancreatic cysts, and kidney cysts; one presented at 13 with 2 spinal hemangioblastomas, one presented at 13 with cerebellar hemangioblastoma, one presented at 30 with cerebellar hemangioblastoma, pancreatic cysts, and kidney cysts. ACMG Evidence Codes: 'PP4' because the patients' phenotypes or family histories are highly specific for VHL disease.",Family,NM_000551.3:c.298dupA,,NM_000551.3:c.298dup,,,NG_008212.3:g.5511dup,LRG_322:g.5511dup,LRG_322t1:c.298dup,NP_000542.1(LRG_322p1):p.(Thr100AsnfsTer32),NC_000003.11:g.10183829dup,3,10183827,.,C,CA,NC_000003.12:g.10142145dup,3,10142143,.,C,CA,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,16572651,298,No,c.298dupA,NM_000551.3,p.Thr100Asnfs*32,T100Nfs*32 (c.298dupA),plus_1_frameshift_variant,3,No,,Unknown,"(Rasmussen et al., 2006)",LK17Y0M,unknown,Mexican,"Patients presenting with cerebellar hemangioblastomas at the Mexican National institute of Neurology and Neurosurgery to were prospectively enrolled alongside family members, resulting in 84 patients in 7 families with VHL mutations, and subjected to peripheral blood draw and PCR-based mutation screening, as well as full clinical screening for symptomatic individuals.. 19 individuals across two families (Family ""B"" and Family ""C"") presented with a c.298dupA mutation, leading to a frameshift. Among these individuals, 2 in Family B and 6 in Family C were asymptomatic at the time of screening (ages 7, 2, 17, 12, 13, 20, 29, and 9). 
 
 Of the 4 symptomatic individuals in Family B, one presented at 44 with cerebellar hemangioblastoma and bilateral retinal angiomas; one presented at 16 with 4 cerebellar hemangioblastomas, 1 bulbar hemangioblastoma, 1 spinal hemangioblastoma, bilateral retinal angiomas, pancreatic cysts, and kidney cysts; one presented at age 26 with cerebellar hemangioblastoma, bilateral retinal angiomas, pancreatic cysts, kidney cysts, and renal cell carcinoma; and one presented at 28 with 1 cerebellar hemangioblastoma. 
 
 Of the 7 symptomatic individuals in Family C, one presented at 45 with cerebellar hemangioblastoma, pancreatic cysts, kidney cysts, and renal cell carcinoma; one presented at age 21 with epididymal cystadenoma; one presented at 36 with 2 cerebellar hemangioblastomas, pancreatic cysts, kidney cysts, hepatic cysts, adrenal cysts, and bilateral renal cell carcinomas; one presented at 20 with spinal hemangioblastoma, pancreatic cysts, and kidney cysts; one presented at 13 with 2 spinal hemangioblastomas, one presented at 13 with cerebellar hemangioblastoma, one presented at 30 with cerebellar hemangioblastoma, pancreatic cysts, and kidney cysts. ACMG Evidence Codes: 'PP4' because the patients' phenotypes or family histories are highly specific for VHL disease.",Family,NM_000551.3:c.298dupA,,NM_000551.3:c.298dup,,,NG_008212.3:g.5511dup,LRG_322:g.5511dup,LRG_322t1:c.298dup,NP_000542.1(LRG_322p1):p.(Thr100AsnfsTer32),NC_000003.11:g.10183829dup,3,10183827,.,C,CA,NC_000003.12:g.10142145dup,3,10142143,.,C,CA,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,16572651,298,No,c.298dupA,NM_000551.3,p.Thr100Asnfs*32,T100Nfs*32 (c.298dupA),plus_1_frameshift_variant,3,No,,Unknown,"(Rasmussen et al., 2006)",LK12Y0M,unknown,Mexican,"Patients presenting with cerebellar hemangioblastomas at the Mexican National institute of Neurology and Neurosurgery to were prospectively enrolled alongside family members, resulting in 84 patients in 7 families with VHL mutations, and subjected to peripheral blood draw and PCR-based mutation screening, as well as full clinical screening for symptomatic individuals.. 19 individuals across two families (Family ""B"" and Family ""C"") presented with a c.298dupA mutation, leading to a frameshift. Among these individuals, 2 in Family B and 6 in Family C were asymptomatic at the time of screening (ages 7, 2, 17, 12, 13, 20, 29, and 9). 
 
 Of the 4 symptomatic individuals in Family B, one presented at 44 with cerebellar hemangioblastoma and bilateral retinal angiomas; one presented at 16 with 4 cerebellar hemangioblastomas, 1 bulbar hemangioblastoma, 1 spinal hemangioblastoma, bilateral retinal angiomas, pancreatic cysts, and kidney cysts; one presented at age 26 with cerebellar hemangioblastoma, bilateral retinal angiomas, pancreatic cysts, kidney cysts, and renal cell carcinoma; and one presented at 28 with 1 cerebellar hemangioblastoma. 
 
 Of the 7 symptomatic individuals in Family C, one presented at 45 with cerebellar hemangioblastoma, pancreatic cysts, kidney cysts, and renal cell carcinoma; one presented at age 21 with epididymal cystadenoma; one presented at 36 with 2 cerebellar hemangioblastomas, pancreatic cysts, kidney cysts, hepatic cysts, adrenal cysts, and bilateral renal cell carcinomas; one presented at 20 with spinal hemangioblastoma, pancreatic cysts, and kidney cysts; one presented at 13 with 2 spinal hemangioblastomas, one presented at 13 with cerebellar hemangioblastoma, one presented at 30 with cerebellar hemangioblastoma, pancreatic cysts, and kidney cysts. ACMG Evidence Codes: 'PP4' because the patients' phenotypes or family histories are highly specific for VHL disease.",Family,NM_000551.3:c.298dupA,,NM_000551.3:c.298dup,,,NG_008212.3:g.5511dup,LRG_322:g.5511dup,LRG_322t1:c.298dup,NP_000542.1(LRG_322p1):p.(Thr100AsnfsTer32),NC_000003.11:g.10183829dup,3,10183827,.,C,CA,NC_000003.12:g.10142145dup,3,10142143,.,C,CA,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,16572651,298,No,c.298dupA,NM_000551.3,p.Thr100Asnfs*32,T100Nfs*32 (c.298dupA),plus_1_frameshift_variant,3,No,,HP:0006880; HP:0001737; HP:0001407; HP:0000107; HP:0000107; HP:0005584,"(Rasmussen et al., 2006)",LK36Y0M,unknown,Mexican,"Patients presenting with cerebellar hemangioblastomas at the Mexican National institute of Neurology and Neurosurgery to were prospectively enrolled alongside family members, resulting in 84 patients in 7 families with VHL mutations, and subjected to peripheral blood draw and PCR-based mutation screening, as well as full clinical screening for symptomatic individuals.. 19 individuals across two families (Family ""B"" and Family ""C"") presented with a c.298dupA mutation, leading to a frameshift. Among these individuals, 2 in Family B and 6 in Family C were asymptomatic at the time of screening (ages 7, 2, 17, 12, 13, 20, 29, and 9). 
 
 Of the 4 symptomatic individuals in Family B, one presented at 44 with cerebellar hemangioblastoma and bilateral retinal angiomas; one presented at 16 with 4 cerebellar hemangioblastomas, 1 bulbar hemangioblastoma, 1 spinal hemangioblastoma, bilateral retinal angiomas, pancreatic cysts, and kidney cysts; one presented at age 26 with cerebellar hemangioblastoma, bilateral retinal angiomas, pancreatic cysts, kidney cysts, and renal cell carcinoma; and one presented at 28 with 1 cerebellar hemangioblastoma. 
 
 Of the 7 symptomatic individuals in Family C, one presented at 45 with cerebellar hemangioblastoma, pancreatic cysts, kidney cysts, and renal cell carcinoma; one presented at age 21 with epididymal cystadenoma; one presented at 36 with 2 cerebellar hemangioblastomas, pancreatic cysts, kidney cysts, hepatic cysts, adrenal cysts, and bilateral renal cell carcinomas; one presented at 20 with spinal hemangioblastoma, pancreatic cysts, and kidney cysts; one presented at 13 with 2 spinal hemangioblastomas, one presented at 13 with cerebellar hemangioblastoma, one presented at 30 with cerebellar hemangioblastoma, pancreatic cysts, and kidney cysts. ACMG Evidence Codes: 'PP4' because the patients' phenotypes or family histories are highly specific for VHL disease.",Family,NM_000551.3:c.298dupA,,NM_000551.3:c.298dup,,,NG_008212.3:g.5511dup,LRG_322:g.5511dup,LRG_322t1:c.298dup,NP_000542.1(LRG_322p1):p.(Thr100AsnfsTer32),NC_000003.11:g.10183829dup,3,10183827,.,C,CA,NC_000003.12:g.10142145dup,3,10142143,.,C,CA,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,16572651,298,No,c.298dupA,NM_000551.3,p.Thr100Asnfs*32,T100Nfs*32 (c.298dupA),plus_1_frameshift_variant,3,No,,Unknown,"(Rasmussen et al., 2006)",LK54Y0M,unknown,Mexican,"Patients presenting with cerebellar hemangioblastomas at the Mexican National institute of Neurology and Neurosurgery to were prospectively enrolled alongside family members, resulting in 84 patients in 7 families with VHL mutations, and subjected to peripheral blood draw and PCR-based mutation screening, as well as full clinical screening for symptomatic individuals.. 19 individuals across two families (Family ""B"" and Family ""C"") presented with a c.298dupA mutation, leading to a frameshift. Among these individuals, 2 in Family B and 6 in Family C were asymptomatic at the time of screening (ages 7, 2, 17, 12, 13, 20, 29, and 9). 
 
 Of the 4 symptomatic individuals in Family B, one presented at 44 with cerebellar hemangioblastoma and bilateral retinal angiomas; one presented at 16 with 4 cerebellar hemangioblastomas, 1 bulbar hemangioblastoma, 1 spinal hemangioblastoma, bilateral retinal angiomas, pancreatic cysts, and kidney cysts; one presented at age 26 with cerebellar hemangioblastoma, bilateral retinal angiomas, pancreatic cysts, kidney cysts, and renal cell carcinoma; and one presented at 28 with 1 cerebellar hemangioblastoma. 
 
 Of the 7 symptomatic individuals in Family C, one presented at 45 with cerebellar hemangioblastoma, pancreatic cysts, kidney cysts, and renal cell carcinoma; one presented at age 21 with epididymal cystadenoma; one presented at 36 with 2 cerebellar hemangioblastomas, pancreatic cysts, kidney cysts, hepatic cysts, adrenal cysts, and bilateral renal cell carcinomas; one presented at 20 with spinal hemangioblastoma, pancreatic cysts, and kidney cysts; one presented at 13 with 2 spinal hemangioblastomas, one presented at 13 with cerebellar hemangioblastoma, one presented at 30 with cerebellar hemangioblastoma, pancreatic cysts, and kidney cysts. ACMG Evidence Codes: 'PP4' because the patients' phenotypes or family histories are highly specific for VHL disease.",Family,NM_000551.3:c.298dupA,,NM_000551.3:c.298dup,,,NG_008212.3:g.5511dup,LRG_322:g.5511dup,LRG_322t1:c.298dup,NP_000542.1(LRG_322p1):p.(Thr100AsnfsTer32),NC_000003.11:g.10183829dup,3,10183827,.,C,CA,NC_000003.12:g.10142145dup,3,10142143,.,C,CA,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,16572651,298,No,c.298dupA,NM_000551.3,p.Thr100Asnfs*32,T100Nfs*32 (c.298dupA),plus_1_frameshift_variant,3,No,,Unknown,"(Rasmussen et al., 2006)",LK13Y0M,unknown,Mexican,"Patients presenting with cerebellar hemangioblastomas at the Mexican National institute of Neurology and Neurosurgery to were prospectively enrolled alongside family members, resulting in 84 patients in 7 families with VHL mutations, and subjected to peripheral blood draw and PCR-based mutation screening, as well as full clinical screening for symptomatic individuals.. 19 individuals across two families (Family ""B"" and Family ""C"") presented with a c.298dupA mutation, leading to a frameshift. Among these individuals, 2 in Family B and 6 in Family C were asymptomatic at the time of screening (ages 7, 2, 17, 12, 13, 20, 29, and 9). 
 
 Of the 4 symptomatic individuals in Family B, one presented at 44 with cerebellar hemangioblastoma and bilateral retinal angiomas; one presented at 16 with 4 cerebellar hemangioblastomas, 1 bulbar hemangioblastoma, 1 spinal hemangioblastoma, bilateral retinal angiomas, pancreatic cysts, and kidney cysts; one presented at age 26 with cerebellar hemangioblastoma, bilateral retinal angiomas, pancreatic cysts, kidney cysts, and renal cell carcinoma; and one presented at 28 with 1 cerebellar hemangioblastoma. 
 
 Of the 7 symptomatic individuals in Family C, one presented at 45 with cerebellar hemangioblastoma, pancreatic cysts, kidney cysts, and renal cell carcinoma; one presented at age 21 with epididymal cystadenoma; one presented at 36 with 2 cerebellar hemangioblastomas, pancreatic cysts, kidney cysts, hepatic cysts, adrenal cysts, and bilateral renal cell carcinomas; one presented at 20 with spinal hemangioblastoma, pancreatic cysts, and kidney cysts; one presented at 13 with 2 spinal hemangioblastomas, one presented at 13 with cerebellar hemangioblastoma, one presented at 30 with cerebellar hemangioblastoma, pancreatic cysts, and kidney cysts. ACMG Evidence Codes: 'PP4' because the patients' phenotypes or family histories are highly specific for VHL disease.",Family,NM_000551.3:c.298dupA,,NM_000551.3:c.298dup,,,NG_008212.3:g.5511dup,LRG_322:g.5511dup,LRG_322t1:c.298dup,NP_000542.1(LRG_322p1):p.(Thr100AsnfsTer32),NC_000003.11:g.10183829dup,3,10183827,.,C,CA,NC_000003.12:g.10142145dup,3,10142143,.,C,CA,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,16572651,298,No,c.298dupA,NM_000551.3,p.Thr100Asnfs*32,T100Nfs*32 (c.298dupA),plus_1_frameshift_variant,3,No,,HP:0009713; HP:0001737; HP:0000107,"(Rasmussen et al., 2006)",LK20Y0M,unknown,Mexican,"Patients presenting with cerebellar hemangioblastomas at the Mexican National institute of Neurology and Neurosurgery to were prospectively enrolled alongside family members, resulting in 84 patients in 7 families with VHL mutations, and subjected to peripheral blood draw and PCR-based mutation screening, as well as full clinical screening for symptomatic individuals.. 19 individuals across two families (Family ""B"" and Family ""C"") presented with a c.298dupA mutation, leading to a frameshift. Among these individuals, 2 in Family B and 6 in Family C were asymptomatic at the time of screening (ages 7, 2, 17, 12, 13, 20, 29, and 9). 
 
 Of the 4 symptomatic individuals in Family B, one presented at 44 with cerebellar hemangioblastoma and bilateral retinal angiomas; one presented at 16 with 4 cerebellar hemangioblastomas, 1 bulbar hemangioblastoma, 1 spinal hemangioblastoma, bilateral retinal angiomas, pancreatic cysts, and kidney cysts; one presented at age 26 with cerebellar hemangioblastoma, bilateral retinal angiomas, pancreatic cysts, kidney cysts, and renal cell carcinoma; and one presented at 28 with 1 cerebellar hemangioblastoma. 
 
 Of the 7 symptomatic individuals in Family C, one presented at 45 with cerebellar hemangioblastoma, pancreatic cysts, kidney cysts, and renal cell carcinoma; one presented at age 21 with epididymal cystadenoma; one presented at 36 with 2 cerebellar hemangioblastomas, pancreatic cysts, kidney cysts, hepatic cysts, adrenal cysts, and bilateral renal cell carcinomas; one presented at 20 with spinal hemangioblastoma, pancreatic cysts, and kidney cysts; one presented at 13 with 2 spinal hemangioblastomas, one presented at 13 with cerebellar hemangioblastoma, one presented at 30 with cerebellar hemangioblastoma, pancreatic cysts, and kidney cysts. ACMG Evidence Codes: 'PP4' because the patients' phenotypes or family histories are highly specific for VHL disease.",Family,NM_000551.3:c.298dupA,,NM_000551.3:c.298dup,,,NG_008212.3:g.5511dup,LRG_322:g.5511dup,LRG_322t1:c.298dup,NP_000542.1(LRG_322p1):p.(Thr100AsnfsTer32),NC_000003.11:g.10183829dup,3,10183827,.,C,CA,NC_000003.12:g.10142145dup,3,10142143,.,C,CA,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,16572651,298,No,c.298dupA,NM_000551.3,p.Thr100Asnfs*32,T100Nfs*32 (c.298dupA),plus_1_frameshift_variant,3,No,,HP:0009713,"(Rasmussen et al., 2006)",LK30Y0M,unknown,Mexican,"Patients presenting with cerebellar hemangioblastomas at the Mexican National institute of Neurology and Neurosurgery to were prospectively enrolled alongside family members, resulting in 84 patients in 7 families with VHL mutations, and subjected to peripheral blood draw and PCR-based mutation screening, as well as full clinical screening for symptomatic individuals.. 19 individuals across two families (Family ""B"" and Family ""C"") presented with a c.298dupA mutation, leading to a frameshift. Among these individuals, 2 in Family B and 6 in Family C were asymptomatic at the time of screening (ages 7, 2, 17, 12, 13, 20, 29, and 9). 
 
 Of the 4 symptomatic individuals in Family B, one presented at 44 with cerebellar hemangioblastoma and bilateral retinal angiomas; one presented at 16 with 4 cerebellar hemangioblastomas, 1 bulbar hemangioblastoma, 1 spinal hemangioblastoma, bilateral retinal angiomas, pancreatic cysts, and kidney cysts; one presented at age 26 with cerebellar hemangioblastoma, bilateral retinal angiomas, pancreatic cysts, kidney cysts, and renal cell carcinoma; and one presented at 28 with 1 cerebellar hemangioblastoma. 
 
 Of the 7 symptomatic individuals in Family C, one presented at 45 with cerebellar hemangioblastoma, pancreatic cysts, kidney cysts, and renal cell carcinoma; one presented at age 21 with epididymal cystadenoma; one presented at 36 with 2 cerebellar hemangioblastomas, pancreatic cysts, kidney cysts, hepatic cysts, adrenal cysts, and bilateral renal cell carcinomas; one presented at 20 with spinal hemangioblastoma, pancreatic cysts, and kidney cysts; one presented at 13 with 2 spinal hemangioblastomas, one presented at 13 with cerebellar hemangioblastoma, one presented at 30 with cerebellar hemangioblastoma, pancreatic cysts, and kidney cysts. ACMG Evidence Codes: 'PP4' because the patients' phenotypes or family histories are highly specific for VHL disease.",Family,NM_000551.3:c.298dupA,,NM_000551.3:c.298dup,,,NG_008212.3:g.5511dup,LRG_322:g.5511dup,LRG_322t1:c.298dup,NP_000542.1(LRG_322p1):p.(Thr100AsnfsTer32),NC_000003.11:g.10183829dup,3,10183827,.,C,CA,NC_000003.12:g.10142145dup,3,10142143,.,C,CA,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,16572651,298,No,c.298dupA,NM_000551.3,p.Thr100Asnfs*32,T100Nfs*32 (c.298dupA),plus_1_frameshift_variant,3,No,,HP:0006880,"(Rasmussen et al., 2006)",LK13Y0M,unknown,Mexican,"Patients presenting with cerebellar hemangioblastomas at the Mexican National institute of Neurology and Neurosurgery to were prospectively enrolled alongside family members, resulting in 84 patients in 7 families with VHL mutations, and subjected to peripheral blood draw and PCR-based mutation screening, as well as full clinical screening for symptomatic individuals.. 19 individuals across two families (Family ""B"" and Family ""C"") presented with a c.298dupA mutation, leading to a frameshift. Among these individuals, 2 in Family B and 6 in Family C were asymptomatic at the time of screening (ages 7, 2, 17, 12, 13, 20, 29, and 9). 
 
 Of the 4 symptomatic individuals in Family B, one presented at 44 with cerebellar hemangioblastoma and bilateral retinal angiomas; one presented at 16 with 4 cerebellar hemangioblastomas, 1 bulbar hemangioblastoma, 1 spinal hemangioblastoma, bilateral retinal angiomas, pancreatic cysts, and kidney cysts; one presented at age 26 with cerebellar hemangioblastoma, bilateral retinal angiomas, pancreatic cysts, kidney cysts, and renal cell carcinoma; and one presented at 28 with 1 cerebellar hemangioblastoma. 
 
 Of the 7 symptomatic individuals in Family C, one presented at 45 with cerebellar hemangioblastoma, pancreatic cysts, kidney cysts, and renal cell carcinoma; one presented at age 21 with epididymal cystadenoma; one presented at 36 with 2 cerebellar hemangioblastomas, pancreatic cysts, kidney cysts, hepatic cysts, adrenal cysts, and bilateral renal cell carcinomas; one presented at 20 with spinal hemangioblastoma, pancreatic cysts, and kidney cysts; one presented at 13 with 2 spinal hemangioblastomas, one presented at 13 with cerebellar hemangioblastoma, one presented at 30 with cerebellar hemangioblastoma, pancreatic cysts, and kidney cysts. ACMG Evidence Codes: 'PP4' because the patients' phenotypes or family histories are highly specific for VHL disease.",Family,NM_000551.3:c.298dupA,,NM_000551.3:c.298dup,,,NG_008212.3:g.5511dup,LRG_322:g.5511dup,LRG_322t1:c.298dup,NP_000542.1(LRG_322p1):p.(Thr100AsnfsTer32),NC_000003.11:g.10183829dup,3,10183827,.,C,CA,NC_000003.12:g.10142145dup,3,10142143,.,C,CA,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,16572651,298,No,c.298dupA,NM_000551.3,p.Thr100Asnfs*32,T100Nfs*32 (c.298dupA),plus_1_frameshift_variant,3,No,,Unknown,"(Rasmussen et al., 2006)",LK29Y0M,unknown,Mexican,"Patients presenting with cerebellar hemangioblastomas at the Mexican National institute of Neurology and Neurosurgery to were prospectively enrolled alongside family members, resulting in 84 patients in 7 families with VHL mutations, and subjected to peripheral blood draw and PCR-based mutation screening, as well as full clinical screening for symptomatic individuals.. 19 individuals across two families (Family ""B"" and Family ""C"") presented with a c.298dupA mutation, leading to a frameshift. Among these individuals, 2 in Family B and 6 in Family C were asymptomatic at the time of screening (ages 7, 2, 17, 12, 13, 20, 29, and 9). 
 
 Of the 4 symptomatic individuals in Family B, one presented at 44 with cerebellar hemangioblastoma and bilateral retinal angiomas; one presented at 16 with 4 cerebellar hemangioblastomas, 1 bulbar hemangioblastoma, 1 spinal hemangioblastoma, bilateral retinal angiomas, pancreatic cysts, and kidney cysts; one presented at age 26 with cerebellar hemangioblastoma, bilateral retinal angiomas, pancreatic cysts, kidney cysts, and renal cell carcinoma; and one presented at 28 with 1 cerebellar hemangioblastoma. 
 
 Of the 7 symptomatic individuals in Family C, one presented at 45 with cerebellar hemangioblastoma, pancreatic cysts, kidney cysts, and renal cell carcinoma; one presented at age 21 with epididymal cystadenoma; one presented at 36 with 2 cerebellar hemangioblastomas, pancreatic cysts, kidney cysts, hepatic cysts, adrenal cysts, and bilateral renal cell carcinomas; one presented at 20 with spinal hemangioblastoma, pancreatic cysts, and kidney cysts; one presented at 13 with 2 spinal hemangioblastomas, one presented at 13 with cerebellar hemangioblastoma, one presented at 30 with cerebellar hemangioblastoma, pancreatic cysts, and kidney cysts. ACMG Evidence Codes: 'PP4' because the patients' phenotypes or family histories are highly specific for VHL disease.",Family,NM_000551.3:c.298dupA,,NM_000551.3:c.298dup,,,NG_008212.3:g.5511dup,LRG_322:g.5511dup,LRG_322t1:c.298dup,NP_000542.1(LRG_322p1):p.(Thr100AsnfsTer32),NC_000003.11:g.10183829dup,3,10183827,.,C,CA,NC_000003.12:g.10142145dup,3,10142143,.,C,CA,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,16572651,298,No,c.298dupA,NM_000551.3,p.Thr100Asnfs*32,T100Nfs*32 (c.298dupA),plus_1_frameshift_variant,3,No,,HP:0006880; HP:0001737; HP:0000107,"(Rasmussen et al., 2006)",LK30Y0M,unknown,Mexican,"Patients presenting with cerebellar hemangioblastomas at the Mexican National institute of Neurology and Neurosurgery to were prospectively enrolled alongside family members, resulting in 84 patients in 7 families with VHL mutations, and subjected to peripheral blood draw and PCR-based mutation screening, as well as full clinical screening for symptomatic individuals.. 19 individuals across two families (Family ""B"" and Family ""C"") presented with a c.298dupA mutation, leading to a frameshift. Among these individuals, 2 in Family B and 6 in Family C were asymptomatic at the time of screening (ages 7, 2, 17, 12, 13, 20, 29, and 9). 
 
 Of the 4 symptomatic individuals in Family B, one presented at 44 with cerebellar hemangioblastoma and bilateral retinal angiomas; one presented at 16 with 4 cerebellar hemangioblastomas, 1 bulbar hemangioblastoma, 1 spinal hemangioblastoma, bilateral retinal angiomas, pancreatic cysts, and kidney cysts; one presented at age 26 with cerebellar hemangioblastoma, bilateral retinal angiomas, pancreatic cysts, kidney cysts, and renal cell carcinoma; and one presented at 28 with 1 cerebellar hemangioblastoma. 
 
 Of the 7 symptomatic individuals in Family C, one presented at 45 with cerebellar hemangioblastoma, pancreatic cysts, kidney cysts, and renal cell carcinoma; one presented at age 21 with epididymal cystadenoma; one presented at 36 with 2 cerebellar hemangioblastomas, pancreatic cysts, kidney cysts, hepatic cysts, adrenal cysts, and bilateral renal cell carcinomas; one presented at 20 with spinal hemangioblastoma, pancreatic cysts, and kidney cysts; one presented at 13 with 2 spinal hemangioblastomas, one presented at 13 with cerebellar hemangioblastoma, one presented at 30 with cerebellar hemangioblastoma, pancreatic cysts, and kidney cysts. ACMG Evidence Codes: 'PP4' because the patients' phenotypes or family histories are highly specific for VHL disease.",Family,NM_000551.3:c.298dupA,,NM_000551.3:c.298dup,,,NG_008212.3:g.5511dup,LRG_322:g.5511dup,LRG_322t1:c.298dup,NP_000542.1(LRG_322p1):p.(Thr100AsnfsTer32),NC_000003.11:g.10183829dup,3,10183827,.,C,CA,NC_000003.12:g.10142145dup,3,10142143,.,C,CA,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,16572651,298,No,c.298dupA,NM_000551.3,p.Thr100Asnfs*32,T100Nfs*32 (c.298dupA),plus_1_frameshift_variant,3,No,,Unknown,"(Rasmussen et al., 2006)",LK9Y0M,unknown,Mexican,"Patients presenting with cerebellar hemangioblastomas at the Mexican National institute of Neurology and Neurosurgery to were prospectively enrolled alongside family members, resulting in 84 patients in 7 families with VHL mutations, and subjected to peripheral blood draw and PCR-based mutation screening, as well as full clinical screening for symptomatic individuals.. 19 individuals across two families (Family ""B"" and Family ""C"") presented with a c.298dupA mutation, leading to a frameshift. Among these individuals, 2 in Family B and 6 in Family C were asymptomatic at the time of screening (ages 7, 2, 17, 12, 13, 20, 29, and 9). 
 
 Of the 4 symptomatic individuals in Family B, one presented at 44 with cerebellar hemangioblastoma and bilateral retinal angiomas; one presented at 16 with 4 cerebellar hemangioblastomas, 1 bulbar hemangioblastoma, 1 spinal hemangioblastoma, bilateral retinal angiomas, pancreatic cysts, and kidney cysts; one presented at age 26 with cerebellar hemangioblastoma, bilateral retinal angiomas, pancreatic cysts, kidney cysts, and renal cell carcinoma; and one presented at 28 with 1 cerebellar hemangioblastoma. 
 
 Of the 7 symptomatic individuals in Family C, one presented at 45 with cerebellar hemangioblastoma, pancreatic cysts, kidney cysts, and renal cell carcinoma; one presented at age 21 with epididymal cystadenoma; one presented at 36 with 2 cerebellar hemangioblastomas, pancreatic cysts, kidney cysts, hepatic cysts, adrenal cysts, and bilateral renal cell carcinomas; one presented at 20 with spinal hemangioblastoma, pancreatic cysts, and kidney cysts; one presented at 13 with 2 spinal hemangioblastomas, one presented at 13 with cerebellar hemangioblastoma, one presented at 30 with cerebellar hemangioblastoma, pancreatic cysts, and kidney cysts. ACMG Evidence Codes: 'PP4' because the patients' phenotypes or family histories are highly specific for VHL disease.",Family,NM_000551.3:c.298dupA,,NM_000551.3:c.298dup,,,NG_008212.3:g.5511dup,LRG_322:g.5511dup,LRG_322t1:c.298dup,NP_000542.1(LRG_322p1):p.(Thr100AsnfsTer32),NC_000003.11:g.10183829dup,3,10183827,.,C,CA,NC_000003.12:g.10142145dup,3,10142143,.,C,CA,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,17392848,492,No,c.492G>T,NM_000551.3,p.Gln164His,Q164H (c.492G>T),missense_variant,1,No,,HP:0009711,"(Kreusel et al., 2007)",LK14Y3M,unknown,705G>T; visual acuity of 20/200; inferior exophytic solitary juxtapapillary capillary retinal angioma (left); no personal of family history of VHL related lesions,"6 of 11 unrelated patients in the study, each presenting with an apparently solitary juxtapapillary capillary retinal angioma, were found to harbour a germline VHL mutation. Patient 5 was found to have the germline mutation 705G>T in the VHL gene and a visual acuity of 20/200. The presented an inferior exophytic solitary juxtapapillary capillary retinal angioma (left eye) and no personal of family history of VHL related lesions. ACMG evidence codes: 'PM6' since this patient presented with no family history of VHL related lesions but the parents did not undergo genetic testing, 'PP4' since the patient presents phenotypes highly specific for a disease with a single genetic etiology.",Patient,NM_000551.3:c.492G>T,,NM_000551.3:c.492G>T,,,NG_008212.3:g.13181G>T,LRG_322:g.13181G>T,LRG_322t1:c.492G>T,NP_000542.1(LRG_322p1):p.(Gln164His),NC_000003.11:g.10191499G>T,3,10191499,.,G,T,NC_000003.12:g.10149815G>T,3,10149815,.,G,T,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,17392848,194,No,c.194C>G,NM_000551.3,p.Ser65Trp,S65W (c.194C>G),missense_variant,2,No,,HP:0009711,"(Kreusel et al., 2007)",LK12Y0M,unknown,407C>G; visual acuity of 20/50; temporal exophytic solitary juxtapapillary capillary retinal angioma (right); no personal history of VHL lesions; positive family history of VHL related lesions,"6 of 11 unrelated patients in the study, each presenting with an apparently solitary juxtapapillary capillary retinal angioma, were found to harbour a germline VHL mutation. Patient 7 was found to have the germline mutation 407C>G of the VHL gene and a visual acuity of 20/50. They presented with a temporal exophytic solitary juxtapapillary capillary retinal angioma (right eye) and no personal history of VHL lesions and a positive family history of VHL related lesions. ACMG evidence codes: 'PM6' since this patient presented with no family history of VHL related lesions but the parents did not undergo genetic testing, 'PP4' since the patient presents phenotypes highly specific for a disease with a single genetic etiology.",Patient,NM_000551.3:c.194C>G,,NM_000551.3:c.194C>G,,,NG_008212.3:g.5407C>G,LRG_322:g.5407C>G,LRG_322t1:c.194C>G,NP_000542.1(LRG_322p1):p.(Ser65Trp),NC_000003.11:g.10183725C>G,3,10183725,.,C,G,NC_000003.12:g.10142041C>G,3,10142041,.,C,G,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,17392848,344,No,c.344A>G,NM_000551.3,p.His115Arg,H115R (c.344A>G),missense_variant,3,No,,HP:0009711; HP:0010797; HP:0002666; HP:0005584,"(Kreusel et al., 2007)",LK5Y6M,unknown,557A>G; visual acuity of 20/125; temporal endophytic solitary juxtapapillary capillary retinal angioma (right); history of epidydimal cystadenoma and CNS hemangiblastoma; RCC; pheochromocytoma; current CNS hemangioblastoma; positive family history of VHL related lesions,"6 of 11 unrelated patients in the study, each presenting with an apparently solitary juxtapapillary capillary retinal angioma, were found to harbour a germline VHL mutation. Patient 8 was found to have the germline mutation 557A>G of the VHL gene and a visual acuity of 20/125. They presented with a temporal endophytic solitary juxtapapillary capillary retinal angioma (right eye) and a history of epidydimal cystadenoma and CNS hemangiblastoma, RCC, pheochromocytoma. They currently presented a CNS hemangioblastoma as well as a positive family history of VHL related lesions. ACMG evidence codes: 'PP4' since the patient presents phenotypes highly specific for a disease with a single genetic etiology.",Patient,NM_000551.3:c.344A>G,,NM_000551.3:c.344A>G,,,NG_008212.3:g.9883A>G,LRG_322:g.9883A>G,LRG_322t1:c.344A>G,NP_000542.1(LRG_322p1):p.(His115Arg),NC_000003.11:g.10188201A>G,3,10188201,.,A,G,NC_000003.12:g.10146517A>G,3,10146517,.,A,G,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,17392848,533,No,c.533T>A,NM_000551.3,p.Leu178Gln,L178Q (c.533T>A),missense_variant,4,No,,HP:0009711; HP:0010797; HP:0002666,"(Kreusel et al., 2007)",LK54Y3M,unknown,746T>A; visual acuity of 20/100; superior exophytic solitary juxtapapillary capillary retinal angioma (right); history of CNS hemangioblastoma; pheochromocytoma; current CNS hemangioblastoma; positive family history of VHL related lesions,"6 of 11 unrelated patients in the study, each presenting with an apparently solitary juxtapapillary capillary retinal angioma, were found to harbour a germline VHL mutation. Patient 9 was found to have the germline mutation 746T>A of the VHL gene and a visual acuity of 20/100. They presenter a superior exophytic solitary juxtapapillary capillary retinal angioma (right eye) and a history of CNS hemangioblastoma, pheochromocytoma as well as a current CNS hemangioblastoma and positive family history of VHL related lesions. ACMG evidence codes: 'PP4' since the patient presents phenotypes highly specific for a disease with a single genetic etiology.",Patient,NM_000551.3:c.533T>A,,NM_000551.3:c.533T>A,,,NG_008212.3:g.13222T>A,LRG_322:g.13222T>A,LRG_322t1:c.533T>A,NP_000542.1(LRG_322p1):p.(Leu178Gln),NC_000003.11:g.10191540T>A,3,10191540,.,T,A,NC_000003.12:g.10149856T>A,3,10149856,.,T,A,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,17392848,292,No,c.292T>C,NM_000551.3,p.Tyr98His,Y98H (c.292T>C),missense_variant,5,No,,HP:0009711,"(Kreusel et al., 2007)",LK34Y0M,unknown,505T>C; visual acuity of 20/30; inferior/temporal endophytic solitary juxtapapillary capillary retinal angioma (left); no personal history of VHL related lesions; positive family history of VHL related lesions,"6 of 11 unrelated patients in the study, each presenting with an apparently solitary juxtapapillary capillary retinal angioma, were found to harbour a germline VHL mutation. Two of these patients (10 and 11) were found to have the germline mutation 505T>C of the VHL gene. Patient 10 had a visual acuity of 20/30 and presented with an inferior/temporal endophytic solitary juxtapapillary capillary retinal angioma (left eye), no personal history of VHL related lesions and a positive family history of VHL related lesions. Patient 11 had a visual acuity of 20/32 and presented with a temporal/inferior/superior endophytic solitary juxtapapillary capillary retinal angioma (left eye), pheochromocytoma and no family history of VHL related lesions. ACMG evidence codes: 'PM6' since this patient presented with no family history of VHL related lesions but the parents did not undergo genetic testing (patient 11), 'PP4' since the patient presents phenotypes highly specific for a disease with a single genetic etiology.",Patient,NM_000551.3:c.292T>C,,NM_000551.3:c.292T>C,,,NG_008212.3:g.5505T>C,LRG_322:g.5505T>C,LRG_322t1:c.292T>C,NP_000542.1(LRG_322p1):p.(Tyr98His),NC_000003.11:g.10183823T>C,3,10183823,.,T,C,NC_000003.12:g.10142139T>C,3,10142139,.,T,C,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,17392848,292,No,c.292T>C,NM_000551.3,p.Tyr98His,Y98H (c.292T>C),missense_variant,6,No,,HP:0009711; HP:0002666,"(Kreusel et al., 2007)",LK12Y6M,unknown,505T>C; visual acuity of 20/32; temporal/inferior/superior endophytic solitary juxtapapillary capillary retinal angioma (left); pheochromocytoma; no family history of VHL related lesions,"6 of 11 unrelated patients in the study, each presenting with an apparently solitary juxtapapillary capillary retinal angioma, were found to harbour a germline VHL mutation. Two of these patients (10 and 11) were found to have the germline mutation 505T>C of the VHL gene. Patient 10 had a visual acuity of 20/30 and presented with an inferior/temporal endophytic solitary juxtapapillary capillary retinal angioma (left eye), no personal history of VHL related lesions and a positive family history of VHL related lesions. Patient 11 had a visual acuity of 20/32 and presented with a temporal/inferior/superior endophytic solitary juxtapapillary capillary retinal angioma (left eye), pheochromocytoma and no family history of VHL related lesions. ACMG evidence codes: 'PM6' since this patient presented with no family history of VHL related lesions but the parents did not undergo genetic testing (patient 11), 'PP4' since the patient presents phenotypes highly specific for a disease with a single genetic etiology.",Patient,NM_000551.3:c.292T>C,,NM_000551.3:c.292T>C,,,NG_008212.3:g.5505T>C,LRG_322:g.5505T>C,LRG_322t1:c.292T>C,NP_000542.1(LRG_322p1):p.(Tyr98His),NC_000003.11:g.10183823T>C,3,10183823,.,T,C,NC_000003.12:g.10142139T>C,3,10142139,.,T,C,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
"Yes - p. was uploaded incorrectly, will need to be fixed on CIViC",7759077,292,No,c.292T>C,NM_000551.3,p.Tyr98His,Y98H (c.292T>C),missense_variant,VHL1,No,,HP:0009711; HP:0002666,"(Brauch et al., 1995)",unknown,unknown,,"Peripheral blood from 116 VHL-affected patients in an interrelated group of 14 German and 2 American families with common ancestry was tested for mutations of the VHL gene, revealing a c.292T>C mutation leading to a p.Tyr89His missense protein change. Among these 116 affected patients, 116 retinal angiomas, 17 CNS hemangioblastomas, 73 pheochromocytomas, and 4 renal cell carcinomas were noted. ACMG Evidence Codes: PP4' because the patients' phenotypes and family histories are highly specific for VHL disease.",Family,NM_000551.3:c.292T>C,,NM_000551.3:c.292T>C,,,NG_008212.3:g.5505T>C,LRG_322:g.5505T>C,LRG_322t1:c.292T>C,NP_000542.1(LRG_322p1):p.(Tyr98His),NC_000003.11:g.10183823T>C,3,10183823,.,T,C,NC_000003.12:g.10142139T>C,3,10142139,.,T,C,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,7759077,292,No,c.292T>C,NM_000551.3,p.Tyr98His,Y98H (c.292T>C),missense_variant,VHL2,No,,HP:0009711; HP:0002666,"(Brauch et al., 1995)",unknown,unknown,,"Peripheral blood from 116 VHL-affected patients in an interrelated group of 14 German and 2 American families with common ancestry was tested for mutations of the VHL gene, revealing a c.292T>C mutation leading to a p.Tyr89His missense protein change. Among these 116 affected patients, 116 retinal angiomas, 17 CNS hemangioblastomas, 73 pheochromocytomas, and 4 renal cell carcinomas were noted. ACMG Evidence Codes: PP4' because the patients' phenotypes and family histories are highly specific for VHL disease.",Family,NM_000551.3:c.292T>C,,NM_000551.3:c.292T>C,,,NG_008212.3:g.5505T>C,LRG_322:g.5505T>C,LRG_322t1:c.292T>C,NP_000542.1(LRG_322p1):p.(Tyr98His),NC_000003.11:g.10183823T>C,3,10183823,.,T,C,NC_000003.12:g.10142139T>C,3,10142139,.,T,C,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,7759077,292,No,c.292T>C,NM_000551.3,p.Tyr98His,Y98H (c.292T>C),missense_variant,VHL4,No,,HP:0009711; HP:0002666,"(Brauch et al., 1995)",unknown,unknown,,"Peripheral blood from 116 VHL-affected patients in an interrelated group of 14 German and 2 American families with common ancestry was tested for mutations of the VHL gene, revealing a c.292T>C mutation leading to a p.Tyr89His missense protein change. Among these 116 affected patients, 116 retinal angiomas, 17 CNS hemangioblastomas, 73 pheochromocytomas, and 4 renal cell carcinomas were noted. ACMG Evidence Codes: PP4' because the patients' phenotypes and family histories are highly specific for VHL disease.",Family,NM_000551.3:c.292T>C,,NM_000551.3:c.292T>C,,,NG_008212.3:g.5505T>C,LRG_322:g.5505T>C,LRG_322t1:c.292T>C,NP_000542.1(LRG_322p1):p.(Tyr98His),NC_000003.11:g.10183823T>C,3,10183823,.,T,C,NC_000003.12:g.10142139T>C,3,10142139,.,T,C,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes - typo in column M phenotype corrected,7759077,292,No,c.292T>C,NM_000551.3,p.Tyr98His,Y98H (c.292T>C),missense_variant,VHL5,No,,HP:0009711; HP:0002666,"(Brauch et al., 1995)",unknown,unknown,,"Peripheral blood from 116 VHL-affected patients in an interrelated group of 14 German and 2 American families with common ancestry was tested for mutations of the VHL gene, revealing a c.292T>C mutation leading to a p.Tyr89His missense protein change. Among these 116 affected patients, 116 retinal angiomas, 17 CNS hemangioblastomas, 73 pheochromocytomas, and 4 renal cell carcinomas were noted. ACMG Evidence Codes: PP4' because the patients' phenotypes and family histories are highly specific for VHL disease.",Family,NM_000551.3:c.292T>C,,NM_000551.3:c.292T>C,,,NG_008212.3:g.5505T>C,LRG_322:g.5505T>C,LRG_322t1:c.292T>C,NP_000542.1(LRG_322p1):p.(Tyr98His),NC_000003.11:g.10183823T>C,3,10183823,.,T,C,NC_000003.12:g.10142139T>C,3,10142139,.,T,C,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,7759077,292,No,c.292T>C,NM_000551.3,p.Tyr98His,Y98H (c.292T>C),missense_variant,VHL8,No,,HP:0009711; HP:0002666,"(Brauch et al., 1995)",unknown,unknown,,"Peripheral blood from 116 VHL-affected patients in an interrelated group of 14 German and 2 American families with common ancestry was tested for mutations of the VHL gene, revealing a c.292T>C mutation leading to a p.Tyr89His missense protein change. Among these 116 affected patients, 116 retinal angiomas, 17 CNS hemangioblastomas, 73 pheochromocytomas, and 4 renal cell carcinomas were noted. ACMG Evidence Codes: PP4' because the patients' phenotypes and family histories are highly specific for VHL disease.",Family,NM_000551.3:c.292T>C,,NM_000551.3:c.292T>C,,,NG_008212.3:g.5505T>C,LRG_322:g.5505T>C,LRG_322t1:c.292T>C,NP_000542.1(LRG_322p1):p.(Tyr98His),NC_000003.11:g.10183823T>C,3,10183823,.,T,C,NC_000003.12:g.10142139T>C,3,10142139,.,T,C,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,7759077,292,No,c.292T>C,NM_000551.3,p.Tyr98His,Y98H (c.292T>C),missense_variant,VHL11,No,,HP:0009711; HP:0002666,"(Brauch et al., 1995)",unknown,unknown,,"Peripheral blood from 116 VHL-affected patients in an interrelated group of 14 German and 2 American families with common ancestry was tested for mutations of the VHL gene, revealing a c.292T>C mutation leading to a p.Tyr89His missense protein change. Among these 116 affected patients, 116 retinal angiomas, 17 CNS hemangioblastomas, 73 pheochromocytomas, and 4 renal cell carcinomas were noted. ACMG Evidence Codes: PP4' because the patients' phenotypes and family histories are highly specific for VHL disease.",Family,NM_000551.3:c.292T>C,,NM_000551.3:c.292T>C,,,NG_008212.3:g.5505T>C,LRG_322:g.5505T>C,LRG_322t1:c.292T>C,NP_000542.1(LRG_322p1):p.(Tyr98His),NC_000003.11:g.10183823T>C,3,10183823,.,T,C,NC_000003.12:g.10142139T>C,3,10142139,.,T,C,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,7759077,292,No,c.292T>C,NM_000551.3,p.Tyr98His,Y98H (c.292T>C),missense_variant,VHL12,No,,HP:0009711; HP:0010797; HP:0002666,"(Brauch et al., 1995)",unknown,unknown,,"Peripheral blood from 116 VHL-affected patients in an interrelated group of 14 German and 2 American families with common ancestry was tested for mutations of the VHL gene, revealing a c.292T>C mutation leading to a p.Tyr89His missense protein change. Among these 116 affected patients, 116 retinal angiomas, 17 CNS hemangioblastomas, 73 pheochromocytomas, and 4 renal cell carcinomas were noted. ACMG Evidence Codes: PP4' because the patients' phenotypes and family histories are highly specific for VHL disease.",Family,NM_000551.3:c.292T>C,,NM_000551.3:c.292T>C,,,NG_008212.3:g.5505T>C,LRG_322:g.5505T>C,LRG_322t1:c.292T>C,NP_000542.1(LRG_322p1):p.(Tyr98His),NC_000003.11:g.10183823T>C,3,10183823,.,T,C,NC_000003.12:g.10142139T>C,3,10142139,.,T,C,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,7759077,292,No,c.292T>C,NM_000551.3,p.Tyr98His,Y98H (c.292T>C),missense_variant,VHL16,No,,HP:0009711; HP:0010797; HP:0002666,"(Brauch et al., 1995)",unknown,unknown,,"Peripheral blood from 116 VHL-affected patients in an interrelated group of 14 German and 2 American families with common ancestry was tested for mutations of the VHL gene, revealing a c.292T>C mutation leading to a p.Tyr89His missense protein change. Among these 116 affected patients, 116 retinal angiomas, 17 CNS hemangioblastomas, 73 pheochromocytomas, and 4 renal cell carcinomas were noted. ACMG Evidence Codes: PP4' because the patients' phenotypes and family histories are highly specific for VHL disease.",Family,NM_000551.3:c.292T>C,,NM_000551.3:c.292T>C,,,NG_008212.3:g.5505T>C,LRG_322:g.5505T>C,LRG_322t1:c.292T>C,NP_000542.1(LRG_322p1):p.(Tyr98His),NC_000003.11:g.10183823T>C,3,10183823,.,T,C,NC_000003.12:g.10142139T>C,3,10142139,.,T,C,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,7759077,292,No,c.292T>C,NM_000551.3,p.Tyr98His,Y98H (c.292T>C),missense_variant,VHL17,No,,HP:0009711; HP:0010797; HP:0002666,"(Brauch et al., 1995)",unknown,unknown,,"Peripheral blood from 116 VHL-affected patients in an interrelated group of 14 German and 2 American families with common ancestry was tested for mutations of the VHL gene, revealing a c.292T>C mutation leading to a p.Tyr89His missense protein change. Among these 116 affected patients, 116 retinal angiomas, 17 CNS hemangioblastomas, 73 pheochromocytomas, and 4 renal cell carcinomas were noted. ACMG Evidence Codes: PP4' because the patients' phenotypes and family histories are highly specific for VHL disease.",Family,NM_000551.3:c.292T>C,,NM_000551.3:c.292T>C,,,NG_008212.3:g.5505T>C,LRG_322:g.5505T>C,LRG_322t1:c.292T>C,NP_000542.1(LRG_322p1):p.(Tyr98His),NC_000003.11:g.10183823T>C,3,10183823,.,T,C,NC_000003.12:g.10142139T>C,3,10142139,.,T,C,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,7759077,292,No,c.292T>C,NM_000551.3,p.Tyr98His,Y98H (c.292T>C),missense_variant,VHL18,No,,HP:0009711; HP:0002666,"(Brauch et al., 1995)",unknown,unknown,,"Peripheral blood from 116 VHL-affected patients in an interrelated group of 14 German and 2 American families with common ancestry was tested for mutations of the VHL gene, revealing a c.292T>C mutation leading to a p.Tyr89His missense protein change. Among these 116 affected patients, 116 retinal angiomas, 17 CNS hemangioblastomas, 73 pheochromocytomas, and 4 renal cell carcinomas were noted. ACMG Evidence Codes: PP4' because the patients' phenotypes and family histories are highly specific for VHL disease.",Family,NM_000551.3:c.292T>C,,NM_000551.3:c.292T>C,,,NG_008212.3:g.5505T>C,LRG_322:g.5505T>C,LRG_322t1:c.292T>C,NP_000542.1(LRG_322p1):p.(Tyr98His),NC_000003.11:g.10183823T>C,3,10183823,.,T,C,NC_000003.12:g.10142139T>C,3,10142139,.,T,C,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,7759077,292,No,c.292T>C,NM_000551.3,p.Tyr98His,Y98H (c.292T>C),missense_variant,VHL22,No,,HP:0009711; HP:0010797; HP:0002666; HP:0005584,"(Brauch et al., 1995)",unknown,unknown,,"Peripheral blood from 116 VHL-affected patients in an interrelated group of 14 German and 2 American families with common ancestry was tested for mutations of the VHL gene, revealing a c.292T>C mutation leading to a p.Tyr89His missense protein change. Among these 116 affected patients, 116 retinal angiomas, 17 CNS hemangioblastomas, 73 pheochromocytomas, and 4 renal cell carcinomas were noted. ACMG Evidence Codes: PP4' because the patients' phenotypes and family histories are highly specific for VHL disease.",Family,NM_000551.3:c.292T>C,,NM_000551.3:c.292T>C,,,NG_008212.3:g.5505T>C,LRG_322:g.5505T>C,LRG_322t1:c.292T>C,NP_000542.1(LRG_322p1):p.(Tyr98His),NC_000003.11:g.10183823T>C,3,10183823,.,T,C,NC_000003.12:g.10142139T>C,3,10142139,.,T,C,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,7759077,292,No,c.292T>C,NM_000551.3,p.Tyr98His,Y98H (c.292T>C),missense_variant,VHL27,No,,HP:0009711; HP:0010797,"(Brauch et al., 1995)",unknown,unknown,,"Peripheral blood from 116 VHL-affected patients in an interrelated group of 14 German and 2 American families with common ancestry was tested for mutations of the VHL gene, revealing a c.292T>C mutation leading to a p.Tyr89His missense protein change. Among these 116 affected patients, 116 retinal angiomas, 17 CNS hemangioblastomas, 73 pheochromocytomas, and 4 renal cell carcinomas were noted. ACMG Evidence Codes: PP4' because the patients' phenotypes and family histories are highly specific for VHL disease.",Family,NM_000551.3:c.292T>C,,NM_000551.3:c.292T>C,,,NG_008212.3:g.5505T>C,LRG_322:g.5505T>C,LRG_322t1:c.292T>C,NP_000542.1(LRG_322p1):p.(Tyr98His),NC_000003.11:g.10183823T>C,3,10183823,.,T,C,NC_000003.12:g.10142139T>C,3,10142139,.,T,C,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,7759077,292,No,c.292T>C,NM_000551.3,p.Tyr98His,Y98H (c.292T>C),missense_variant,VHL28,No,,HP:0009711; HP:0002666,"(Brauch et al., 1995)",unknown,unknown,,"Peripheral blood from 116 VHL-affected patients in an interrelated group of 14 German and 2 American families with common ancestry was tested for mutations of the VHL gene, revealing a c.292T>C mutation leading to a p.Tyr89His missense protein change. Among these 116 affected patients, 116 retinal angiomas, 17 CNS hemangioblastomas, 73 pheochromocytomas, and 4 renal cell carcinomas were noted. ACMG Evidence Codes: PP4' because the patients' phenotypes and family histories are highly specific for VHL disease.",Family,NM_000551.3:c.292T>C,,NM_000551.3:c.292T>C,,,NG_008212.3:g.5505T>C,LRG_322:g.5505T>C,LRG_322t1:c.292T>C,NP_000542.1(LRG_322p1):p.(Tyr98His),NC_000003.11:g.10183823T>C,3,10183823,.,T,C,NC_000003.12:g.10142139T>C,3,10142139,.,T,C,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,7759077,292,No,c.292T>C,NM_000551.3,p.Tyr98His,Y98H (c.292T>C),missense_variant,VHL34,No,,HP:0010797; HP:0005584,"(Brauch et al., 1995)",unknown,unknown,,"Peripheral blood from 116 VHL-affected patients in an interrelated group of 14 German and 2 American families with common ancestry was tested for mutations of the VHL gene, revealing a c.292T>C mutation leading to a p.Tyr89His missense protein change. Among these 116 affected patients, 116 retinal angiomas, 17 CNS hemangioblastomas, 73 pheochromocytomas, and 4 renal cell carcinomas were noted. ACMG Evidence Codes: PP4' because the patients' phenotypes and family histories are highly specific for VHL disease.",Family,NM_000551.3:c.292T>C,,NM_000551.3:c.292T>C,,,NG_008212.3:g.5505T>C,LRG_322:g.5505T>C,LRG_322t1:c.292T>C,NP_000542.1(LRG_322p1):p.(Tyr98His),NC_000003.11:g.10183823T>C,3,10183823,.,T,C,NC_000003.12:g.10142139T>C,3,10142139,.,T,C,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,7759077,292,No,c.292T>C,NM_000551.3,p.Tyr98His,Y98H (c.292T>C),missense_variant,3127,No,,HP:0009711; HP:0010797; HP:0002666,"(Brauch et al., 1995)",unknown,unknown,,"Peripheral blood from 116 VHL-affected patients in an interrelated group of 14 German and 2 American families with common ancestry was tested for mutations of the VHL gene, revealing a c.292T>C mutation leading to a p.Tyr89His missense protein change. Among these 116 affected patients, 116 retinal angiomas, 17 CNS hemangioblastomas, 73 pheochromocytomas, and 4 renal cell carcinomas were noted. ACMG evidence codes: 'PP1', with the allele significant cosegregation with the disease in family members for a gene known to cause the described syndrome, and 'PP4' because the patients' phenotypes or family histories are highly specific for VHL disease.",Family,NM_000551.3:c.292T>C,,NM_000551.3:c.292T>C,,,NG_008212.3:g.5505T>C,LRG_322:g.5505T>C,LRG_322t1:c.292T>C,NP_000542.1(LRG_322p1):p.(Tyr98His),NC_000003.11:g.10183823T>C,3,10183823,.,T,C,NC_000003.12:g.10142139T>C,3,10142139,.,T,C,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,7759077,292,No,c.292T>C,NM_000551.3,p.Tyr98His,Y98H (c.292T>C),missense_variant,3476,No,,HP:0009711; HP:0010797; HP:0002666,"(Brauch et al., 1995)",unknown,unknown,,"Peripheral blood from 116 VHL-affected patients in an interrelated group of 14 German and 2 American families with common ancestry was tested for mutations of the VHL gene, revealing a c.292T>C mutation leading to a p.Tyr89His missense protein change. Among these 116 affected patients, 116 retinal angiomas, 17 CNS hemangioblastomas, 73 pheochromocytomas, and 4 renal cell carcinomas were noted. ACMG evidence codes: 'PP1', with the allele significant cosegregation with the disease in family members for a gene known to cause the described syndrome, and 'PP4' because the patients' phenotypes or family histories are highly specific for VHL disease.",Family,NM_000551.3:c.292T>C,,NM_000551.3:c.292T>C,,,NG_008212.3:g.5505T>C,LRG_322:g.5505T>C,LRG_322t1:c.292T>C,NP_000542.1(LRG_322p1):p.(Tyr98His),NC_000003.11:g.10183823T>C,3,10183823,.,T,C,NC_000003.12:g.10142139T>C,3,10142139,.,T,C,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes p. was uploaded incorrectly; will need to be fixed on CIViC,9488521,500,No,c.500G>A,NM_000551.3,p.Arg167Gln,R167Q (c.500G>A),missense_variant,1,No,,HP:0009711; HP:0010797; HP:0002894,"(Curley et al., 1998)",E29Y0M; LK29Y0M,unknown,Legacy Nomenclature - 713G>A,"A proband presenting in Texas with bilateral retinal angionams, hemanigoblastoma, and pancreatic cancer tested positive for a c.500G>A mutation leading to a p.Arg167Glu protein change. Subsequent testing of the patient's family revealed two affected siblings with VHL diseas, one with a pancreatic tumor and bilateral renal cysts, and the other with a pancreatic tumor renal cysts, and ovarian cysts. The mother of these women is also affected with bilateral retinal angiomas, and a maternal aunt died of cerebellar hemangioblastoma. Two affected cousins, one with retinal angioma and pancreatic cysts, and the other with cerebellar hemangioblastoma, were also reported.  ACMG Evidence Codes:  'PP4' because the pattern of presentations observed is highly specific for VHL disease.",Patient,NM_000551.3:c.500G>A,,NM_000551.3:c.500G>A,,,NG_008212.3:g.13189G>A,LRG_322:g.13189G>A,LRG_322t1:c.500G>A,NP_000542.1(LRG_322p1):p.(Arg167Gln),NC_000003.11:g.10191507G>A,3,10191507,.,G,A,NC_000003.12:g.10149823G>A,3,10149823,.,G,A,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,9488521,500,No,c.500G>A,NM_000551.3,p.Arg167Gln,R167Q (c.500G>A),missense_variant,1,No,,HP:0009711; HP:0002894,"(Curley et al., 1998)",unknown,unknown,,"A proband presenting in Texas with bilateral retinal angionams, hemanigoblastoma, and pancreatic cancer tested positive for a c.500G>A mutation leading to a p.Arg167Glu protein change. Subsequent testing of the patient's family revealed two affected siblings with VHL diseas, one with a pancreatic tumor and bilateral renal cysts, and the other with a pancreatic tumor renal cysts, and ovarian cysts. The mother of these women is also affected with bilateral retinal angiomas, and a maternal aunt died of cerebellar hemangioblastoma. Two affected cousins, one with retinal angioma and pancreatic cysts, and the other with cerebellar hemangioblastoma, were also reported.  ACMG Evidence Codes:  'PP4' because the pattern of presentations observed is highly specific for VHL disease.",Patient,NM_000551.3:c.500G>A,,NM_000551.3:c.500G>A,,,NG_008212.3:g.13189G>A,LRG_322:g.13189G>A,LRG_322t1:c.500G>A,NP_000542.1(LRG_322p1):p.(Arg167Gln),NC_000003.11:g.10191507G>A,3,10191507,.,G,A,NC_000003.12:g.10149823G>A,3,10149823,.,G,A,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,9488521,500,No,c.500G>A,NM_000551.3,p.Arg167Gln,R167Q (c.500G>A),missense_variant,1,No,,HP:0002894; HP:0000107; HP:0000138,"(Curley et al., 1998)",unknown,unknown,,"A proband presenting in Texas with bilateral retinal angionams, hemanigoblastoma, and pancreatic cancer tested positive for a c.500G>A mutation leading to a p.Arg167Glu protein change. Subsequent testing of the patient's family revealed two affected siblings with VHL diseas, one with a pancreatic tumor and bilateral renal cysts, and the other with a pancreatic tumor renal cysts, and ovarian cysts. The mother of these women is also affected with bilateral retinal angiomas, and a maternal aunt died of cerebellar hemangioblastoma. Two affected cousins, one with retinal angioma and pancreatic cysts, and the other with cerebellar hemangioblastoma, were also reported.  ACMG Evidence Codes:  'PP4' because the pattern of presentations observed is highly specific for VHL disease.",Patient,NM_000551.3:c.500G>A,,NM_000551.3:c.500G>A,,,NG_008212.3:g.13189G>A,LRG_322:g.13189G>A,LRG_322t1:c.500G>A,NP_000542.1(LRG_322p1):p.(Arg167Gln),NC_000003.11:g.10191507G>A,3,10191507,.,G,A,NC_000003.12:g.10149823G>A,3,10149823,.,G,A,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,9488521,500,No,c.500G>A,NM_000551.3,p.Arg167Gln,R167Q (c.500G>A),missense_variant,1,No,,HP:0009711; HP:0002666,"(Curley et al., 1998)",unknown,unknown,,"A proband presenting in Texas with bilateral retinal angionams, hemanigoblastoma, and pancreatic cancer tested positive for a c.500G>A mutation leading to a p.Arg167Glu protein change. Subsequent testing of the patient's family revealed two affected siblings with VHL diseas, one with a pancreatic tumor and bilateral renal cysts, and the other with a pancreatic tumor renal cysts, and ovarian cysts. The mother of these women is also affected with bilateral retinal angiomas, and a maternal aunt died of cerebellar hemangioblastoma. Two affected cousins, one with retinal angioma and pancreatic cysts, and the other with cerebellar hemangioblastoma, were also reported.  ACMG Evidence Codes:  'PP4' because the pattern of presentations observed is highly specific for VHL disease.",Patient,NM_000551.3:c.500G>A,,NM_000551.3:c.500G>A,,,NG_008212.3:g.13189G>A,LRG_322:g.13189G>A,LRG_322t1:c.500G>A,NP_000542.1(LRG_322p1):p.(Arg167Gln),NC_000003.11:g.10191507G>A,3,10191507,.,G,A,NC_000003.12:g.10149823G>A,3,10149823,.,G,A,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,9488521,500,No,c.500G>A,NM_000551.3,p.Arg167Gln,R167Q (c.500G>A),missense_variant,1,No,,HP:0006880,"(Curley et al., 1998)",E25Y0M; LK25Y0M,unknown,,"A proband presenting in Texas with bilateral retinal angionams, hemanigoblastoma, and pancreatic cancer tested positive for a c.500G>A mutation leading to a p.Arg167Glu protein change. Subsequent testing of the patient's family revealed two affected siblings with VHL diseas, one with a pancreatic tumor and bilateral renal cysts, and the other with a pancreatic tumor renal cysts, and ovarian cysts. The mother of these women is also affected with bilateral retinal angiomas, and a maternal aunt died of cerebellar hemangioblastoma. Two affected cousins, one with retinal angioma and pancreatic cysts, and the other with cerebellar hemangioblastoma, were also reported.  ACMG Evidence Codes:  'PP4' because the pattern of presentations observed is highly specific for VHL disease.",Patient,NM_000551.3:c.500G>A,,NM_000551.3:c.500G>A,,,NG_008212.3:g.13189G>A,LRG_322:g.13189G>A,LRG_322t1:c.500G>A,NP_000542.1(LRG_322p1):p.(Arg167Gln),NC_000003.11:g.10191507G>A,3,10191507,.,G,A,NC_000003.12:g.10149823G>A,3,10149823,.,G,A,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,9488521,500,No,c.500G>A,NM_000551.3,p.Arg167Gln,R167Q (c.500G>A),missense_variant,1,No,,HP:0009711; HP:0001737,"(Curley et al., 1998)",unknown,unknown,,"A proband presenting in Texas with bilateral retinal angionams, hemanigoblastoma, and pancreatic cancer tested positive for a c.500G>A mutation leading to a p.Arg167Glu protein change. Subsequent testing of the patient's family revealed two affected siblings with VHL diseas, one with a pancreatic tumor and bilateral renal cysts, and the other with a pancreatic tumor renal cysts, and ovarian cysts. The mother of these women is also affected with bilateral retinal angiomas, and a maternal aunt died of cerebellar hemangioblastoma. Two affected cousins, one with retinal angioma and pancreatic cysts, and the other with cerebellar hemangioblastoma, were also reported.  ACMG Evidence Codes:  'PP4' because the pattern of presentations observed is highly specific for VHL disease.",Patient,NM_000551.3:c.500G>A,,NM_000551.3:c.500G>A,,,NG_008212.3:g.13189G>A,LRG_322:g.13189G>A,LRG_322t1:c.500G>A,NP_000542.1(LRG_322p1):p.(Arg167Gln),NC_000003.11:g.10191507G>A,3,10191507,.,G,A,NC_000003.12:g.10149823G>A,3,10149823,.,G,A,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Re-run VV,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Yes - minor change to c.,16391622,595,No,c.595del,NM_000551.3,p.Glu199Serfs*3,E199Sfs*3 (c.595del),minus_1_frameshift_variant,1,Yes,,HP:0009711,"(Valenzuela et al, 2005)",E7Y0M,F,FLAG FOR PM4 due to frameshift ,"This case report details a girl who presented at 7 with apparent Coate's disease, and when followed up later at 15 was found to have multiple severe retinal hemangiomas leading to retinal detachment. Genetic testing revealed a heterozygous c.594G>Del mutation in the VHL gene, leading to a frameshift after codon 128 and a premature stop at codon 158. ACMG Evidence Codes:  'PP4' because the pattern of presentations observed is highly specific for VHL disease. ",Patient,NM_000551.3:c.595del,,NM_000551.3:c.595del,,,NG_008212.3:g.13284del,LRG_322:g.13284del,LRG_322t1:c.595del,NP_000542.1:p.(Glu199SerfsTer3),NC_000003.11:g.10191602del,3,10191600,.,TG,T,NC_000003.12:g.10149918del,3,10149916,.,TG,T,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",